



Published in final edited form as:

J Med Chem. 2013 July 25; 56(14): 5917–5930. doi:10.1021/jm4007017.

Synthesis and Structure-activity Relationship Studies of *O*-Biphenyl-3-yl Carbamates as Peripherally Restricted Fatty Acid Amide Hydrolase Inhibitors

Guillermo Moreno-Sanz^{a,b,†}, Andrea Duranti^{c,‡}, Laurin Melzig^a, Claudio Fiorelli^a, Gian Filippo Ruda^a, Giampiero Colombano^a, Paola Mestichelli^c, Silvano Sanchini^c, Andrea Tontini^c, Marco Mor^d, Tiziano Bandiera^a, Rita Scarpelli^a, Giorgio Tarzia^c, and Daniele Piomelli^{a,b,*}

^aDrug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, I-16163 Genova, Italy

^bDepartments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, Irvine, USA, 92697-4621

^cDipartimento di Scienze Biomolecolari, University of Urbino “Carlo Bo”, Piazza del Rinascimento 6, I-61029 Urbino, Italy,

^dDipartimento Farmaceutico, University of Parma, Viale G. P. Usberti 27/A, I-43124 Parma, Italy

Abstract

The peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor URB937 (**3**, cyclohexylcarbamic acid 3'-carbamoyl-6-hydroxybiphenyl-3-yl ester) is extruded from the brain and spinal cord by the Abcg2 efflux transporter. Despite its inability to enter the central nervous system (CNS), **3** exerts profound antinociceptive effects in mice and rats, which result from the inhibition of FAAH in peripheral tissues and the consequent enhancement of anandamide signaling at CB₁ cannabinoid receptors localized on sensory nerve endings. In the present study, we examined the structure-activity relationships (SAR) for the biphenyl region of compound **3**, focusing on the carbamoyl and hydroxyl groups in the distal and proximal phenyl rings. Our SAR studies generated a new series of peripherally restricted FAAH inhibitors and identified compound **35** (cyclohexylcarbamic acid 3'-carbamoyl-5-hydroxybiphenyl-3-yl ester) as the most potent brain-impermeant FAAH inhibitor disclosed to date.

Keywords

FAAH; *O*-biphenyl-3-yl carbamates; URB937; SAR; peripheral FAAH inhibitors

*Corresponding Author daniele.piomelli@iit.it; Phone: +3901071781509; fax, +3901071781228..

†These authors contributed equally to design and perform the research.

The authors declare the following competing financial interests: patents protecting the class of compounds disclosed in this paper were filed by the University of California Irvine, Istituto Italiano di Tecnologia, Università degli Studi di Urbino “Carlo Bo”, and Università degli Studi di Parma on behalf of following individuals: Piomelli, Daniele; Moreno-Sanz, Guillermo; Bandiera, Tiziano; Mor, Marco, and Tarzia, Giorgio.

INTRODUCTION

The therapeutic exploitation of the endocannabinoid system with exogenous agonists is limited by the undesired side effects caused by indiscriminate activation of cannabinoid type-1 (CB₁) receptors, particularly in the brain.¹ An alternative strategy to direct CB₁ receptor targeting is to upregulate the signaling activity of the endogenous cannabinoid ligands, arachidonylethanolamide (anandamide)² and 2-arachidonoyl-*sn*-glycerol (2-AG),³ by blocking their intracellular degradation. Anandamide is released on demand by stimulated neurons² and inhibitors of the enzyme responsible for its hydrolytic cleavage, fatty acid amide hydrolase (FAAH), have been shown to increase anandamide levels and activate central and peripheral CB₁ receptors without causing signs of cannabinoid intoxication.^{4,5}

Outside the central nervous system (CNS), CB₁ receptors are found in organs such as liver, kidney and intestine, as well as in peripheral sensory terminals and dorsal root ganglia (DRG) neurons.⁶ Evidence suggests that therapeutic gain devoid of central liability can be achieved in conditions such as pain and metabolic syndrome by targeting these peripheral receptors.^{7,8} Thus, developing pharmacological agents that do not cross the blood-brain barrier (BBB) provides a potential approach to identify endocannabinoid-based therapies that are both safe and effective. Indeed, synthetic efforts aimed at creating CB₁ receptor agonists and antagonists with restricted access to the CNS have been reported.^{9,10,11,12} In those studies, the main strategies adopted to limit access of compounds of interest to the CNS were either to increase the compounds' topological polar surface area (TPSA)¹¹ or to exploit the recognition by drug transporters present in the blood-brain barrier (BBB).¹²

Selective activation of peripheral CB₁ receptors by endogenously produced anandamide was first achieved with compound URB937 (**3**, cyclohexylcarbamic acid 3'-carbamoyl-6-hydroxybiphenyl-3-yl ester, Figure 1), which blocks FAAH activity only outside the CNS through an irreversible mechanism.¹³ Compound **3** inhibits visceral and inflammatory pain responses in rodents by reducing nociceptive inputs to the spinal cord.¹³ Genetic and pharmacological studies have shown that this compound is extruded from the CNS by the ATP-binding cassette transporter Abcg2 (ABCG2 in humans).¹⁴ Furthermore, Abcg2 limits the access of **3** not only to the CNS, but also to the feto-placental unit of pregnant rodents.¹⁵ Recognition by Abcg2 may be exploited, therefore, as a novel strategy to develop therapeutic agents devoid of CNS-mediated effects and, possibly, safe to be used during pregnancy.¹⁶

We have previously shown that introduction of a hydroxyl group in the para position of the proximal phenyl ring of cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester (**1**, URB597, Figure 1) generates the peripherally restricted derivative **3** (Figure 1).¹³ Conversely, removing the carbamoyl moiety from the distal phenyl ring yields cyclohexylcarbamic acid 6-hydroxybiphenyl-3-yl ester, a compound that readily enters the brain (**2**, URB694, Figure 1).^{17,18} These observations suggest that the R¹ and R² regions (Figure 1) are essential to limit the penetration of *O*-biphenyl-3-yl carbamate FAAH inhibitors into the CNS. To elucidate the substitutions in R¹ and R² that best combine inhibitory potency and lack of brain penetration, we progressively modified the R¹ and R²

regions in the scaffold of **3** and tested the new compounds for their ability to inhibit FAAH activity in vitro and in vivo. Dose-response exploration studies allowed us to establish a hierarchy among the different substituents based on their access to the brain. Furthermore, the involvement of Abcg2 in the peripheral distribution of the new compounds was tested using the selective Abcg2 inhibitor, Ko-143.¹⁹ These studies allowed us to identify a series of novel peripherally restricted FAAH inhibitors, including the highly potent compound **35**, and obtain new insights on the structural requirements underpinning the impaired access of these agents to the CNS.

CHEMISTRY

Different synthetic approaches were utilized for the preparation of compounds **7a–g** and **11a–c**, bearing structural modifications on the distal phenyl ring (Scheme 1 and 2).

Compounds **7a–c** were prepared by the introduction of the targeted structural variations at the last step of the synthesis via a Suzuki cross-coupling reaction directly on the common intermediate **6**, obtained from **4**²⁰ through an *O*-debenzylation by using boron tribromide in dichloromethane (Scheme 1). Alternatively, compounds **7d–g** were prepared using a synthetic methodology recently reported for the preparation of multigram scale of **3**.²⁰ The intermediates **5d–g** were obtained from **4** through a Suzuki cross-coupling reaction and converted into the final compounds via a *O*-debenzylation reaction employing either cyclohexene and Pd/C in dioxane or boron tribromide in dichloromethane (Scheme 1).

Compounds **11a–c** were obtained in three steps starting from **8**^{13,21}, through a Suzuki cross-coupling reaction followed by carbamoylation and Pd/C catalyzed hydrogenative deprotection (Scheme 2).

Compound **15**¹³ was obtained in a three-step synthetic procedure starting from the commercially available aldehyde **12** which was converted into phenol derivative **13** through a Dakin oxidation²² followed by a Suzuki cross-coupling reaction to give **14** that was then treated with cyclohexyl isocyanate in acetonitrile to afford the carbamate **15** (Scheme 3).

The synthetic procedure for the preparation of compound **21** is reported in Scheme 4. Starting from the commercially available aldehyde **16**, which was protected as acetal **17**,²³ a two-step sequence was employed to obtain the *O*-benzylated bromide **18**²⁴ via a nucleophilic aromatic substitution with benzyl alcohol in the presence of potassium *tert*-butoxide, followed by hydrolysis of the acetal group under acidic condition. The intermediate **18** was efficiently converted into the biphenyl aldehyde **19** under ligand-free Suzuki cross-coupling conditions²⁵ by reacting with 3-carbamoylphenylboronic acid in aqueous potassium carbonate in the presence of palladium acetate. Compound **19** was then reduced under standard conditions to the corresponding alcohol **20** that was *O*-debenzylated and selectively converted with cyclohexyl isocyanate into the final compound **21**.

The synthetic procedure for the preparation of compound **29** is described in Scheme 5. Starting from **22**, a Friedel-Crafts acylation produced compound **23** which was oxidized to carboxylic acid **24** by a two-step sequence consisting in a Claisen condensation with diethyl oxalate followed by an oxidative cleavage with potassium peroxymonosulfate.²⁶ The

conversion of **24** into **25** was carried out using boron tribromide in dichloromethane. Compound **25** was then chemoselectively transformed into the *O*-benzylester **26**²⁷ that, after a Suzuki cross-coupling reaction, gave **27**. Conversion of the phenol derivative **27** into the carboxylic acid **29** was carried out through a carbamoylation reaction by using cyclohexyl isocyanate in acetonitrile/ethanol followed by Pd/C catalysed hydrogenolysis with cyclohexene in dioxane.

Scheme 6 reports the synthesis of compound **35** from **31** that was converted by a nucleophilic aromatic substitution in **32**.²⁸ A ligand-free Suzuki cross coupling reaction was utilized²⁹ to afford the corresponding biphenyl derivative **33** that was quantitatively debenzylated to obtain compound **34**. Attempts to selectively mono-carbamoylate **34** in the desired carbamate **35** were troublesome. Compound **34** was treated with cyclohexyl isocyanate (1.1 equiv.) in presence of triethylamine or 4-(dimethylamino)-pyridine (DMAP) in acetonitrile at room temperature for 12h to afford mixtures containing the di-carbamoylated derivative **36** as the major side product. In the specific, we observed the formation of (0.6: 1.3: 1.0) and (1.3: 1.0: 2.3) mixtures of compounds (**34**: **35**: **36**) by using triethylamine (1.1 equiv.) and DMAP (0.1 equiv.) respectively. Eventually, the use of cyclohexyl isocyanate in *N,N*-dimethylformamide at room temperature in presence of copper chloride as promoter³⁰ yielded a (1:2:1) mixture of compounds (**34**: **35**: **36**), which were separated by chromatographic purification. Alternatively, attempts to carry out selective mono-protection of compound **34** with *tert*-butyldimethylsilyl chloride (TBSCl) or triisopropylsilyl chloride (TIPSCl) also failed.

Compound **41** was obtained in a four-step synthetic procedure starting from the commercially available phenol **37**, that was converted in the corresponding triflate **38**³¹ and directly used in the Suzuki cross coupling reaction to afford **39**. Compound **39** was selectively mono-demethylated to **40** using boron tribromide in dichloromethane and then converted to the carbamate **41** under standard conditions (Scheme 7).

RESULTS

Previous studies have shown that compound **3** inhibits FAAH activity in liver and other peripheral tissues of mice with a median effective dose (ED₅₀) of 0.2 mg/kg (intraperitoneal, i.p.), which is 200 times lower than the ED₅₀ for FAAH inhibition in the brain (40 mg/kg).¹³ The present study evaluated the effects that structural modifications at the meta position of the distal phenyl ring (R¹ region) and the para or meta positions of the proximal phenyl ring (R² region) exert on the inhibitory potency and systemic distribution of **3**. Median concentrations to inhibit FAAH activity (IC₅₀) were determined in vitro using rat brain homogenates. FAAH inhibition was also measured ex vivo in liver and brain tissue of mice 1 h after systemic administration of test compounds (1 mg/kg, i.p.). Since *O*-biphenyl-3-yl carbamates inhibit FAAH through a covalent, irreversible mechanism,³² the degree of FAAH inhibition measured ex vivo provides a useful estimate of the amount of compound reaching that tissue.^{14,15}

Analogues of **3** bearing different substituents on the meta- position of the distal phenyl ring

The results of explorative chemistry targeting the meta position of the distal phenyl ring (R^1 region) of **3** are summarized in Table 1. Substituting the carbamoyl group with a methyl (**11a**), 1-hydroxyethyl (**11b**) or hydroxymethyl (**11c**) group yielded compounds that retained FAAH inhibitory activity *in vitro*, but readily accessed the CNS *in vivo*: **11a–c** produced similar inhibitory effects on FAAH activity in brain and liver. Likewise, the methylketone derivative **7a** displayed good brain penetration *in vivo*, along with increased *in vitro* potency on FAAH (Table 1). These results confirm that the carbamoyl functionality in the R^1 region of **3** plays a key role in the peripheral distribution of this compound. This idea was further tested by preparing new compounds in which such functionality was progressively alkylated to a secondary (**7d**) or tertiary (**7e**) amide. When administered *in vivo* (1 mg/kg, *i.p.*), both **7d** and **7e** displayed impaired access to the brain, but maintained the ability to block FAAH activity in the liver (Table 1). A dose–exploration study revealed that **7d** and **7e** gain access to the brain at higher dosages, similarly to what previously found for **3**,¹³ possibly by saturating the mechanism that mediates their extrusion from the brain (Figure 2a). Interestingly, the ED_{50} values of these compounds for brain FAAH inhibition *ex vivo* (**3**, 40 mg/kg; **7d**, 15 mg/kg; **7e**, 3.5 mg/kg) progressively decreased as the number of methyl substituents linked to the carbamoyl moiety was increased (Figure 2a). The reverse amide **7c** displayed significantly higher brain penetration relative to **3**, **7d** and **7e** at all doses tested (Figure 2a). The involvement of the Abcg2 transporter in restricting the access of **7d** and **7e** to the brain was tested by pre-administration of the selective inhibitor Ko-143 (15 mg/kg, *i.p.*). Pharmacological blockade of Abcg2 allowed sub-effective doses of **3** and **7d** to inhibit FAAH activity in the brain, but failed to do so with **7e** (Figure 2c). We interpret these findings to indicate that a primary (**3**) or secondary (**7d**) carbamoyl moiety is a key determinant for the interaction of *O*-biphenyl-3-yl carbamate FAAH inhibitors with Abcg2 *in vivo*. By contrast, the asymmetric tissue distribution of **7e** at low doses appears to be independent of Abcg2.

To further test the relevance of the carbamoyl group in the distal ring of **3**, and probe its possible role in the interaction with Abcg2 acting as a H-bond donor, we synthesized and tested the carboxylic acid derivative **7b** (Table 1). The compound displayed impaired access to the brain, but failed to fully inhibit liver FAAH activity at 1 mg/kg (30% inhibition, Table 1). By increasing the dosage to 3 mg/kg, we were able to improve the blockade of liver FAAH activity (66% inhibition, Table 1), still without affecting brain FAAH activity. These findings suggest that **7b** has restricted access to the CNS. However, we did not further pursue the characterization of this compound due to its relatively low potency both *in vitro* and *in vivo*. On the other hand, the corresponding bioisosteric sulphonamide (**7f**) and methylsulphone (**7g**) derivatives were potent, single-digit nanomolar FAAH inhibitors *in vitro* and were effective at inhibiting liver FAAH activity *in vivo* (1mg/kg, *i.p.*), while having significantly reduced brain penetration (Table 1). In agreement with the results obtained with the primary and secondary carbamoyl derivatives **3** and **7d**, we found that **7f** displayed a more strongly restricted access to the CNS compared to **7g**, with brain ED_{50} values of 75 and 3 mg/kg, respectively (Figure 2b). However, pharmacological blockade of Abcg2 with Ko-143 did not increase the access of a sub-effective dose of **7f** (40 mg/kg) or

7g (1mg/kg) to the brain (Figure 2c), indicating that these compounds are excluded from the CNS by a mechanism that is independent of Abcg2.

Analogues of **3** with different substituents on the meta- or para- position of the proximal phenyl ring

Next, we turned our attention to the SAR exploration of the R² region of compound **3**. The results are summarized in Table 2. We hypothesized that the hydroxyl group in the para position of the proximal phenyl ring, which differentiates **3** from the globally active inhibitor **1** (Figure 1), might be a key element in the peripheral distribution of **3**. Supporting this idea, we previously showed that the *p*-methoxy derivative **15** readily accesses the brain following systemic administration.¹³ In agreement with this finding, hydroxyl-containing substituents such as the hydroxymethyl **21** and the carboxylic acid **29** were also peripherally restricted when administered at the dosage of 1 mg/kg (Table 2). Compound **21** behaved similarly to **3** and **7d**, in that it inhibited brain FAAH when given at high doses (ED₅₀ = 15 mg/kg, Figure 3a) and gained access to the brain when co-administered with the Abcg2 inhibitor Ko-143 (Figure 3b). By contrast, **29** failed to enter the brain even at the highest dose tested (75 mg/kg, Figure 3a). A similar behavior was displayed by the sulfate derivative **30** (Table 2, Figure 3a). Neither **29** nor **30** entered the brain, despite pre-treatment with Ko-143 (Figure 3b), indicating that Abcg2 is not involved in restricting their access to the CNS. It is likely that the presence of absolute charges on the surface of **29** and **30** hinders their diffusion across the BBB.

Lastly, we asked whether relocation of the hydroxyl group of **3** from the para- to the meta-position on the proximal phenyl ring affects FAAH activity and brain penetration. The *m*hydroxy derivative **35** retained both a strong inhibitory potency toward FAAH in vitro (IC₅₀ = 0.5 mg/kg) and a marked peripheral distribution (Table 2). A dose exploration study revealed that **35** had a markedly restricted access to the brain (ED₅₀ = 75 mg/kg, Figure 3a). For comparison, compound **3** inhibited brain FAAH with an ED₅₀ of 40 mg/kg. The inability of **35** to access the brain appears to require Abcg2, since pharmacological blockade of this transporter allowed a high dose of **35** (40 mg/kg) to inhibit central FAAH activity (Figure 3b). Similarly to what found for **15**, the asymmetric tissue distribution of **35** was lost in the corresponding *m*methoxy derivative **41**, which inhibited FAAH in liver and brain to a similar extent after systemic administration (1 mg/kg, Table 2).

CONCLUSIONS

Previous studies have identified compound **3** as a potent and selective FAAH inhibitor, whose passage through the blood-tissue barriers of the CNS and feto-placental unit is restricted at by the Abcg2 transporter.^{14,15} Despite this restricted systemic distribution, **3** exhibits marked anti-hyperalgesic and anti-allodynic properties in mice and rats,¹³ suggesting that peripherally restricted FAAH inhibitors might represent a novel class of clinically relevant analgesics.²¹ The primary objective of the present study was to identify new brain-impermeant FAAH inhibitors, which could be used both as tools to understand the role of anandamide in peripheral tissues and as potential candidates for preclinical development. The identification of brain-impermeant drugs is often based on the use of

cellular efflux transport assays. However, these in vitro systems do not realistically capture the complexity of the BBB. For this reason, we opted for testing the newly synthesized compounds in vivo, using inhibition of FAAH activity in brain and liver tissues as a measure of central and peripheral exposure to the drug. The contribution of Abcg2 was examined using Ko-143, a selective inhibitor of this transporter. Our SAR exploration of two pharmacophoric regions in the scaffold of **3** allowed us to identify several novel FAAH inhibitors with restricted access to the brain. Among them, the *m*-hydroxyl derivative **35** showed the greatest inhibitory potency in vitro ($IC_{50} = 0.5$ nM) and the lowest brain penetration in vivo ($ED_{50} = 75$ mg/kg). This compound thus provides a valuable addition to our still limited armamentarium of peripherally restricted FAAH inhibitors.

The present study also offered several insights on the molecular mechanism responsible for the peripheral distribution of *O*-biphenyl-3-yl carbamate FAAH inhibitors. By showing that progressive alkylation of the carboxamide group in the distal phenyl ring of **3** (R^1 region) leads to a higher degree of brain penetration, our results confirm a key role for this moiety in determining the peripheral distribution of **3**. Contrary to what was found for the primary and secondary amides (**3** and **7d**), the restricted access to the brain of the tertiary amide **7e** was not mediated by Abcg2. A plausible interpretation of this finding is that the carboxamide hydrogen bond donors may be necessary for **3** and **7d** to interact with Abcg2, possibly through H-bonding.

We were able to confirm the key role played by the hydroxyl substituent of the proximal ring of **3** in the peripheral distribution of *O*-biphenyl-3-yl carbamate FAAH inhibitors. Some flexibility is allowed around this motif, however, since both the *p*- and *m*-hydroxy (**3** and **35**), as well as the *p*-hydroxymethyl derivative **21** behaved as substrates for Abcg2 in vivo, gaining access to the brain after pharmacological blockade of the transporter by Ko-143. By contrast, compounds **29** and **30** did not enter the brain, even at the highest dosage tested, and their distribution was not influenced by Ko-143 treatment. The case of the sulfate derivative **30** is particularly significant. This compound was initially synthesized to test the putative role of phenolsulfotransferases (PSTs) in the peripheralization of **3**. Sulfate conjugation is known to increase the affinity of Abcg2 for its substrates,³³ and PSTs to co-localize with the transporter in brain, intestinal epithelium and other tissues.³⁴ However, the transfer of the sulfate group is expected to occur in the cytosol of epithelial cells, where PSTs and the substrate-binding site of Abcg2 are located, once the compound has diffused through the apical side of the membrane. The present findings suggest that the higher PSA of these two compounds might preclude their diffusion through cellular membranes and therefore their access to the CNS.

Even though further experiments are required to fully characterize the mechanisms that preclude *O*-biphenyl-3-yl carbamates from entering the brain, our results may be relevant to the design of new pharmacological agents with restricted access to the CNS. In the case of the Abcg2/ABCG2 transporter, the structure of which has not been yet resolved, the information gleaned from the present SAR studies may be useful to understand the interaction between the pharmacophoric sites of **35** and amino acid residues of the transporter involved in substrate recognition.

EXPERIMENTAL SECTION

Animals

Adult male Swiss-Webster mice (25-30 g) were kept in a temperature-controlled environment with a 12-h light/12-h dark cycle receiving standard chow and water ad libitum. All procedures met the National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee of the University of California, Irvine.

Drug administration

FAAH inhibitors were dissolved in warm saline/PEG400/Tween80 (18:1:1) under sonication, and were administered by i.p. or subcutaneous injection between the shoulder blades. Ko-143 (Tocris, Ellisville, MO) was dissolved in the same vehicle containing 30% DMSO (Sigma, St. Louis, MO) and administered by i.p. injection 20 min prior to FAAH inhibitors.

Tissue processing

Mice were slightly anesthetized with isoflurane and killed by decapitation 1 hour after drug injections. Brain and liver were immediately removed and frozen in liquid N₂. Samples were weighed and homogenized in 10 volumes of ice-cold Tris-HCl (50 mM, 5–9 vol., pH 7.5) containing 0.32M sucrose. Homogenates were centrifuged at 1000×g for 10 min at 4°C and supernatants were collected and tested for protein concentration using a bicinchoninic acid (BCA) assay kit (Pierce, Rockford, IL).

Ex vivo FAAH activity assay

FAAH activity was measured at 37°C for 30 min in 0.5mL of Tris buffer (50 mM, pH 7.5) containing fatty acid-free bovine serum albumin (BSA) (0.05%, w/v), protein from tissue homogenates (50 µg from rat brain, 10 µg from liver), non-radioactive anandamide (10 µM) and anandamide[ethanolamine-³H] (10,000 cpm, specific activity 60 Ci/mmol, ARC, St. Louis, MO) as substrate. Reactions were stopped with chloroform/methanol (1:1, 1 mL) and radioactivity was measured in the aqueous layer by liquid scintillation counting. For in vitro IC₅₀ determination, homogenates (50 µg from rat brain) were pre-incubated with inhibitors for 20 min at 37°C prior to substrate addition.

Chemicals, materials and methods—Solvents and reagents were obtained from commercial suppliers and were used without further purification. NMR experiments were run on a Bruker AC 200 spectrometer (200.07 MHz for ¹H, and 50.31 MHz for ¹³C) and on a Bruker Avance III 400 system (400.13 MHz for ¹H, and 100.62 MHz for ¹³C), equipped with a BBI probe and Z-gradients. Spectra were acquired at 300 K, using deuterated dimethylsulfoxide (DMSO-*d*₆) or deuterated chloroform (chloroform-*d*) as solvents. Chemical shifts (δ) for ¹H and ¹³C spectra are reported in parts per million (ppm) using the residual non-deuterated solvent resonance as the internal standard (for chloroform-*d*: 7.26 ppm, ¹H and 77.16 ppm, ¹³C; for DMSO-*d*₆: 2.50 ppm, ¹H; 39.52 ppm, ¹³C). Data are reported as follows: chemical shift (sorted in descending order), multiplicity (indicated as: s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; m, multiplet and combinations thereof),

coupling constants (J) in Hertz (Hz) and integration. UPLC/MS analyses were run on a Waters ACQUITY UPLC/MS system consisting of a Single Quadropole Detector (SQD) Mass Spectrometer (MS) equipped with an Electrospray Ionization (ESI) interface and a Photodiode Array (PDA) Detector. PDA range was 210-400 nm. ESI in positive and negative mode was applied. Mobile phases: (A) 10mM NH_4OAc in H_2O , pH 5; (B) 10mM NH_4OAc in $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (95:5) pH 5. Analyses were performed either with method A, B or C. *Method A*: gradient 5 to 95% B over 3 min; flow rate 0.5 mL/min; temperature 40 °C. Pre column: Vanguard BEH C_{18} (1.7 μm 2.1x5mm). Column: BEH C_{18} (1.7 μm 2.1x50mm). *Method B*: gradient 0 to 50% B over 3 min; flow rate 0.5 mL/min; temperature 40 °C. Pre column: VanGuard HSS T3 C_{18} (1.7 μm 2.1x5 mm). Column HSS T3 (1.8 μm 2.1 x 50mm). *Method C*: gradient: 50 to 100% B over 3 min, flow rate 0.5 mL/min; temperature 40 °C. Pre column: Vanguard BEH C_{18} (1.7 μm 2.1x5mm). Column: BEH C_{18} (1.7 μm 2.1x50mm). Flash column chromatography was performed automatically on Teledyne ISCO apparatus (CombiFlash® Rf) with pre-packed silica gel columns of different sizes (Redisep) or manually on silica gel (Kieselgel60, 0.040-0.063 mm, Merck). TLC analyses were performed on precoated silica gel on aluminum sheets (Kieselgel 60 F254, Merck). Purifications by preparative HPLC/MS were run on a Waters Autopurification system consisting of a 3100 Single Quadropole Detector (SQD) Mass Spectrometer (MS) equipped with an Electrospray Ionization (ESI) interface and a 2998 Photodiode Array (PDA) Detector. HPLC system included a 2747 Sample Manager, 2545 Binary Gradient Module, System Fluidic Organizer and 515 HPLC Pump. PDA range was 210-400 nm. Purifications were performed on a XBridge™ Prep C_{18} OBD column (100x19mmID, particle size 5 μm) with a XBridge™ Prep C_{18} (10x19 mmID, particle size 5 μm) Guard Cartridge. Mobile phase was 10 mM NH_4OAc in H_2O at pH 5 adjusted with AcOH (A) and 10 mM NH_4OAc in $\text{CH}_3\text{CN} -\text{H}_2\text{O}$ (95:5) at pH 5 (B). ESI in positive and negative mode was used. All final compounds displayed 95% purity as determined by UPLC analysis.

General Procedure for the Synthesis of Carbamates 5d–g and 7a–c

(Procedure A)—A mixture of compound **4** (or **6**) (1.0 equiv.), the appropriate aryl boronic acid (or aryl boronic ester) (1.5 equiv.), CsOAc (2.0 equiv.) in dioxane (0.1 M) was degassed with a stream of N_2 for 30 min. PdCl_2dppf (0.05 equiv.) was added and the reaction mixture was heated at 80 °C until UPLC-MS analysis revealed completion of the reaction. The reaction mixture was cooled down to room temperature and a saturated aqueous NH_4Cl solution was added (3 mL). The aqueous phase was separated and extracted with EtOAc (2 x 15 mL). The combined organic phases were washed with brine and dried (Na_2SO_4). After evaporation of the solvent, the residue was purified by flash chromatography (SiO_2) eluting with a gradient of EtOAc/ cyclohexane or MeOH/ DCM.

General procedure for the Synthesis of Carbamates 7d–g (Procedure B)—

Compound **5d** (**5e**, or **5f**, or **5g**) (1.0 equiv.) was heated in a 1:5 mixture of cyclohexene/ EtOH (0.2 M) at 60 °C in presence of 10% Pd/C (catalyst loading: 2.5% w/w) until UPLC-MS analysis revealed completion of the reaction. The reaction mixture was filtered through a pad of Celite and concentrated in vacuo. The residue was purified by flash chromatography (SiO_2) eluting with a gradient of cyclohexane/ EtOAc or MeOH/ DCM.

General procedure for the Synthesis of Phenols 9a,b and 14 (Procedure C)—A mixture of **8** (or **13**) (1.0 equiv.), the appropriate boronic acid (1.2 equiv.) and Na₂CO₃ (5 equiv., 10% aqueous solution) in toluene (0.2 M) was degassed with a stream of N₂ for 30 min. Pd(PPh₃)₄ (0.05 equiv.) was added and the reaction mixture was stirred at reflux for 12 h, cooled down to room temperature, and filtered through a pad of Celite. 2N HCl (5 mL) was added and the mixture was extracted with EtOAc. The combined organic layers were dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (SiO₂) eluting with cyclohexane/ EtOAc or MeOH/ DCM.

General procedure for the Synthesis of Carbamates 10a,b and 15 (Procedure D)—To a solution of **9a** (or **9b**, or **14**) (1.0 equiv.) in CH₃CN (0.4 M), *c*-hexyl-isocyanate (1.1 equiv.) and Et₃N (1.1 equiv.) were added. The mixture was stirred for 5 h at reflux, cooled down to room temperature and concentrated in vacuo. The residue was purified by flash chromatography (SiO₂) eluting with cyclohexane /EtOAc.

General procedure for the Synthesis of Carbamates 11a–c (Procedure E)—Compound **10a** (or **10b**) (1.0 equiv.) was heated in EtOAc/EtOH (1:1, 0.1 M) (for **10a**) or EtOH (0.1 M) (for **10b**) at 50 °C under H₂ atmosphere (4 atm) in presence of 10% Pd/C (catalyst loading: 10% w/w) for 4h. The mixture was then cooled down to room temperature and filtered through a pad of Celite. After evaporation of the solvent, the residue was purified by flash chromatography (SiO₂) eluting with cyclohexane/EtOAc.

Cyclohexylcarbamic Acid 3'-Acetamido-6-benzyloxybiphenyl-3-yl Ester (5d)—The title compound **5d** was prepared according to general procedure A using compound **4** (0.202 g, 0.50 mmol), PdCl₂dppf (18.3 mg, 0.025 mmol), CsOAc (192 mg, 1.00 mmol) and *N*-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (195 mg, 0.75 mmol); reaction time: 2 h. The residue was purified by flash chromatography (0 to 50% EtOAc in cyclohexane) to afford **5d** as a white solid. 43 mg, 19%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.85 (s, 1H), 7.77–7.72 (m, 1H), 7.65 (d, *J* = 7.7 Hz, 1H), 7.41 (t, *J* = 7.7 Hz, 1H), 7.34–7.26 (m, 5H), 7.12 (d, *J* = 2.7 Hz, 1H), 7.05 (dd, *J* = 2.7, 8.8 Hz, 1H), 6.98 (d, *J* = 8.8 Hz, 1H), 6.19 (d, *J* = 4.8 Hz, 1H), 5.04–4.99 (m, 1H), 4.99 (s, 2H), 3.59–3.51 (m, 1H), 2.90 (d, *J* = 4.8 Hz, 3H), 2.03–1.96 (m, 2H), 1.77–1.69 (m, 2H), 1.65–1.58 (m, 1H), 1.41–1.30 (m, 2H), 1.28–1.14 (m, 3H). MS (ES) C₂₈H₃₀N₂O₄ requires *m/z* 458, found 459 [M+H]⁺.

Cyclohexylcarbamic Acid 6-Benzyloxy-3'-dimethylcarbamoylbiphenyl-3-yl Ester (5e)—The title compound **5e** was prepared according to general procedure A using compound **4** (0.404 g, 1.0 mmol), PdCl₂dppf (36.6 mg, 0.05 mmol), CsOAc (0.384 mg, 2.0 mmol) and *N,N*-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.413 g, 1.5 mmol); reaction time: 6 h. The residue was purified by flash chromatography (0 to 50% EtOAc in cyclohexane) to afford **5e** as a colourless solid. 229 mg, 48%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.65–7.55 (m, 2H), 7.47–7.35 (m, 2H), 7.35–7.27 (m, 5H), 7.17–7.10 (m, 1H), 7.07 (d, *J* = 8.81 Hz, 1H), 7.00 (d, *J* = 8.82 Hz, 1H), 5.03 (s, 2H), 4.94–4.85 (m, 1H), 3.64–3.51 (m, 1H), 2.95 (s, 6H), 2.09–1.95 (m, 2H), 1.80–1.67 (m, 2H), 1.67–1.56 (m, 1H), 1.46–1.30 (m, 2H), 1.30–1.12 (m, 3H). MS (ES) C₂₉H₃₂N₂O₄ requires *m/z* 472, found 473 [M+H]⁺.

Cyclohexylcarbamic Acid 6-Benzyloxy-3'-sulfamoylbiphenyl-3-yl Ester (5f)—

The title compound **5f** was prepared according to general procedure A using compound **4** (162 mg, 0.4 mmol), PdCl₂dppf (14.6 mg, 0.02 mmol), CsOAc (154 mg, 0.80 mmol) and (3-sulfamoylphenyl)boronic acid (201 mg, 0.60 mmol); reaction time: 8 h. The residue was purified by flash chromatography (0 to 30% EtOAc in cyclohexane) to afford **5f** as a white solid. 105 mg, 55%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.17 (s, 1H), 7.93 (d, *J* = 7.4 Hz, 1H), 7.83 (d, *J* = 7.9 Hz, 1H), 7.75 (dd, *J* = 7.4, 7.9 Hz, 1H), 7.37–7.28 (m, 5H), 7.16 (d, *J* = 2.7 Hz, 1H), 7.11 (dd, *J* = 2.7, 8.8 Hz, 1H), 7.03 (d, *J* = 8.8 Hz, 1H), 5.04 (s, 2H), 4.93 (d, *J* = 7.7 Hz, 1H), 4.61 (s, 2H), 3.61–3.52 (m, 1H), 2.05–1.98 (m, 2H), 1.78–1.70 (m, 2H), 1.66–1.60 (m, 1H), 1.41–1.31 (m, 2H), 1.31–1.15 (m, 3H). MS (ESI): C₂₆H₂₈N₂O₅S requires *m/z* 480, found 481 [M+H]⁺.

Cyclohexylcarbamic Acid 6-Benzyloxy-3'-methylsulfonylbiphenyl-3-yl Ester (5g)—

The title compound **5g** was prepared according to general procedure A using compound **4** (162 mg, 0.4 mmol), PdCl₂dppf (14.6 mg, 0.02 mmol), CsOAc (154 mg, 0.80 mmol) and (3-methylsulfonylphenyl)boronic acid (200 mg, 0.60 mmol); reaction time: 4 h. The residue was purified by flash chromatography (0 to 30% EtOAc in cyclohexane) to afford **5g** as a colourless solid. 148 mg, 77%. ¹H NMR (400 MHz, chloroform-*d*) δ 8.19 (s, 1H), 7.86 (d, *J* = 7.9 Hz, 1H), 7.82 (d, *J* = 7.7 Hz, 1H), 7.56 (dd, *J* = 7.7, 7.9 Hz, 1H), 7.35–7.27 (m, 5H), 7.16 (d, *J* = 2.7 Hz, 1H), 7.12 (dd, *J* = 2.7, 8.8 Hz, 1H), 7.04 (d, *J* = 8.8 Hz, 1H), 5.05 (s, 2H), 4.95 (d, *J* = 7.86 Hz, 1H), 3.61–3.52 (m, 1H), 2.89 (s, 3H), 2.06–1.98 (m, 2H), 1.78–1.70 (m, 2H), 1.66–1.60 (m, 1H), 1.44–1.32 (m, 2H), 1.23 (m, 3H). MS (ESI) C₂₇H₂₉NO₅S requires *m/z* 479, found 480 [M+H]⁺.

Cyclohexylcarbamic Acid 3-Bromo-4-hydroxyphenyl Ester (6)—

To a solution of **4** (4.04 g, 10.0 mmol) in dry DCM (50 mL) at –78 °C, BBr₃ (20.0 mL, 1.0 M solution in DCM) was slowly added under Ar atmosphere and the reaction mixture stirred at –78 °C for 2 h and then quenched with saturated aqueous NH₄Cl solution. The aqueous layer was extracted with DCM (3 x 50 mL) and the combined organic phases were washed with brine and dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (0 to 20% EtOAc in cyclohexane) to afford **6** as a white solid. 3.06 g, 97%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.27 (d, *J* = 2.5 Hz, 1H), 6.97 (dd, *J* = 2.5, 8.8 Hz, 1H), 6.93 (d, *J* = 8.8 Hz, 1H), 5.59 (s, 1H), 4.89 (d, *J* = 6.9 Hz, 1H), 3.59–3.50 (m, 1H), 2.04–1.96 (m, 2H), 1.78–1.70 (m, 2H), 1.66–1.59 (m, 1H), 1.43–1.31 (m, 2H), 1.27–1.14 (m, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 154.1, 151.8, 143.9, 126.4, 122.5, 116.4, 108.8, 50.2, 33.0, 25.6, 25.0. MS (ESI) C₁₃H₁₆BrNO₃ requires *m/z* 313, 315, found 314, 316 [M+H]⁺.

Cyclohexylcarbamic Acid 3'-Acetyl-6-hydroxybiphenyl-3-yl Ester (7a)—

The title compound **7a** was prepared according to general procedure A using compound **6** (0.157 g, 0.5 mmol), PdCl₂dppf (18.3 mg, 0.025 mmol), CsOAc (192 mg, 1.00 mmol) and 3-methoxyphenylboronic acid (114 mg, 0.75 mmol); reaction time: 5 h. The crude was purified by flash chromatography (0 to 40% EtOAc in cyclohexane) to afford **7a** as a colourless solid. 109 mg, 62%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.63 (s, 1H), 8.11 (s, 1H), 7.91 (d, *J* = 7.8 Hz, 1H), 7.82 (d, *J* = 7.8 Hz, 1H), 7.62–7.52 (m, 2H), 7.04 (s, 1H), 6.96–

6.91 (m, 2H), 3.35–3.28 (m, 1H), 2.62 (s, 3H), 1.86–1.79 (m, 2H), 1.74–1.66 (m, 2H), 1.60–1.52 (m, 1H), 1.33–1.19 (m, 4H), 1.15–1.07 (m, 1H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 198.4, 154.4, 151.8, 144.1, 138.6, 137.2, 134.2, 129.1, 128.9, 127.4, 127.1, 123.6, 122.6, 116.8, 50.2, 33.0, 27.3, 25.6, 25.0. MS (ES) $\text{C}_{21}\text{H}_{23}\text{NO}_4$ requires m/z 353, found 354 [M+H] $^+$.

Cyclohexylcarbamic Acid 3'-Carboxy-6-hydroxybiphenyl-3-yl Ester (7b)—The title compound **7b** was prepared according to general procedure A using compound **6** (0.157 g, 0.5 mmol), PdCl₂dppf (18.3 mg, 0.025 mmol), CsOAc (192 mg, 1.00 mmol) and 3-phenylboronic acid (124 mg, 0.75 mmol); reaction time: 12 h. The crude was purified by flash chromatography (0 to 10% MeOH in DCM) to afford **7b** as a yellow solid. 28 mg, 16%. ^1H NMR (400 MHz, DMSO- d_6) δ 12.90 (s, 1H), 9.62 (s, 1H), 8.12 (s, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.53 (t, J = 7.7 Hz, 1H), 6.99 (s, 1H), 6.92 (s, 2H), 3.34–3.30 (m, 1H), 1.83–1.79 (m, 2H), 1.72–1.67 (m, 2H), 1.57–1.53 (m, 1H), 1.30–1.18 (m, 4H), 1.16–1.05 (m, 1H). MS (ESI) $\text{C}_{20}\text{H}_{21}\text{NO}_5$ requires m/z 355, found 356 [M+H] $^+$.

Cyclohexylcarbamic Acid 3'-Acetamido-6-hydroxybiphenyl-3-yl Ester (7c)—The title compound **7c** was prepared according to general procedure A using compound **6** (157 mg, 0.50 mmol), PdCl₂dppf (18.3 mg, 0.025 mmol), CsOAc (192 mg, 1.00 mmol) and (3-acetamidophenyl)boronic acid (179 mg, 0.75 mmol); reaction time: 6 h. The crude was purified by flash chromatography (0 to 50% EtOAc in cyclohexane) to afford **7c** as an off-white solid. 110 mg, 60%. ^1H NMR (400 MHz, DMSO- d_6) δ 9.94 (s, 1H), 9.47 (s, 1H), 7.71 (s, 1H), 7.57 (d, J = 7.9 Hz, 2H), 7.30 (t, J = 7.9 Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H), 6.89 (s, 2H), 3.29 (s, 1H), 2.04 (s, 3H), 1.81 (d, J = 9.5 Hz, 2H), 1.75–1.65 (m, 3H), 1.55 (d, J = 12.5 Hz, 1H), 1.33–1.17 (m, 4H), 1.18–1.04 (m, 1H). ^{13}C NMR (101 MHz, DMSO- d_6) δ 168.7, 154.4, 151.7, 144.0, 139.5, 138.7, 128.7, 128.2, 124.3, 123.5, 122.0, 120.2, 118.0, 116.7, 50.2, 33.0, 25.6, 25.0, 24.5. MS (ES) $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_4$ requires m/z 368, found 369 [M+H] $^+$.

Cyclohexylcarbamic Acid 6-Hydroxy-3'-methylcarbamoylebiphenyl-3-yl Ester (7d)—The title compound **7d** was prepared according to general procedure B using compound **5d** (41.3 mg, 0.09 mmol) and 10% Pd/C (16.5 mg); reaction time: 2 h. The residue was purified by flash chromatography (0 to 2% MeOH in DCM) to afford **7d** as a white solid. 23 mg, 56%. ^1H NMR (400 MHz, chloroform- d) δ 7.65 (d, J = 7.7 Hz, 1H), 7.58 (s, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.35 (dd, J = 7.7, 7.7 Hz, 1H), 6.90–6.83 (m, 3H), 6.73 (d, J = 8.7 Hz, 1H), 6.67 (d, J = 4.8 Hz, 1H), 5.08 (bd, J = 8.1 Hz, 1H), 3.56–3.51 (m, 1H), 2.90 (d, J = 4.8 Hz, 3H), 2.01–1.96 (m, 2H), 1.76–1.70 (m, 2H), 1.65–1.59 (m, 1H), 1.41–1.30 (m, 2H), 1.27–1.16 (m, 3H). ^{13}C NMR (101 MHz, chloroform- d) δ 171.3, 168.7, 155.0, 150.9, 144.2, 137.7, 134.8, 132.2, 128.8, 127.4, 126.4, 123.5, 122.2, 117.2, 60.5, 50.4, 33.3, 25.6, 24.9. MS (ES) $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_4$ requires m/z 368, found 369 [M+H] $^+$.

Cyclohexylcarbamic Acid 3'-dimethylcarbamoyle-6-hydroxybiphenyl-3-yl Ester (7e)—To a solution of **5e** (227 mg, 0.48 mmol) in dry DCM (5 mL) at -78 °C, BBr₃ (0.96 mL, 1.0 M solution in DCM) was slowly added under Ar atmosphere. The reaction was warmed to room temperature, stirred for 1 h and then quenched with saturated aqueous

NH₄Cl solution. The aqueous solution was extracted with EtOAc (3 × 20 mL) and the organic phase dried (Na₂SO₄). After evaporation of solvent, the residue was purified by flash chromatography (0 to 4% MeOH in DCM) to afford **5e** as a colourless solid. 133 mg, 72%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.59 (s, 1H), 7.64–7.54 (m, 3H), 7.50–7.41 (m, 1H), 7.33 (d, *J* = 7.5 Hz, 1H), 7.00 (s, 1H), 6.97–6.89 (m, 2H), 3.33–3.28 (m, 1H), 3.01–2.93 (m, 6H), 1.85–1.78 (m, 2H), 1.71–1.66 (m, 2H), 1.59–1.51 (m, 1H), 1.33–1.17 (m, 4H), 1.16–1.04 (m, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.6, 154.4, 151.8, 144.1, 138.2, 136.6, 130.3, 128.5, 127.9, 127.5, 125.9, 123.6, 122.4, 116.8, 55.3, 50.2, 33.0, 25.6, 25.0. MS (ES) C₂₂H₂₆N₂O₄ requires *m/z* 382, found 383 [M+H]⁺.

Cyclohexylcarbamic Acid 6-Hydroxy-3'-sulfamoylbiphenyl-3-yl Ester (7f)—The title compound **7f** was prepared according to general procedure B using compound **5f** (106 mg, 0.22 mmol), and 10% Pd/C (42.4 mg); reaction time: 2 h. The residue was purified by flash chromatography (0 to 50% EtOAc in cyclohexane) to afford **7f** as a white solid. 75 mg, 87%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.72–9.68 (m, 1H), 8.01 (s, 1H), 7.79 (d, *J* = 7.8 Hz, 1H), 7.77–7.73 (m, 1H), 7.62–7.56 (m, 2H), 7.35 (s, 2H), 7.01 (s, 1H), 6.96–6.93 (m, 2H), 3.39–3.26 (m, 1H), 1.85–1.77 (m, 2H), 1.74–1.66 (m, 2H), 1.59–1.52 (m, 1H), 1.32–1.19 (m, 4H), 1.18–1.08 (m, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 154.4, 151.8, 144.4, 144.1, 138.9, 132.7, 129.07, 126.8, 126.5, 124.3, 123.6, 122.9, 116.9, 50.2, 33.0, 25.6, 25.0. MS (ESI) C₁₉H₂₂N₂O₅S requires *m/z* 390, found 391 [M+H]⁺.

Cyclohexylcarbamic Acid 6-Hydroxy-3'-methylsulfonylbiphenyl-3-yl Ester (7g)—The title compound **7g** was prepared according to general procedure B using compound **5g** (149 mg, 0.31 mmol), and 10% Pd/C (59.6 mg); reaction time: 2 h. The residue was purified by flash chromatography (0 to 50% EtOAc in cyclohexane) to afford **7g** as a colourless solid. 109 mg, 90%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.75 (s, 1H), 8.09–8.07 (m, 1H), 7.94–7.90 (m, 1H), 7.88–7.84 (m, 1H), 7.71–7.65 (m, 1H), 7.60 (d, *J* = 7.9 Hz, 1H), 7.11–7.08 (m, 1H), 6.98–6.92 (m, 2H), 3.34–3.27 (m, 1H), 3.25 (s, 3H), 1.85–1.77 (m, 2H), 1.74–1.66 (m, 2H), 1.59–1.52 (m, 1H), 1.32–1.16 (m, 4H), 1.16–1.06 (m, 1H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 153.9, 151.3, 143.7, 140.7, 138.8, 134.0, 129.1, 127.2, 125.9, 125.2, 123.2, 122.7, 116.4, 49.7, 43.6, 32.6, 25.1, 24.6. MS (ESI) C₂₀H₂₃NO₅S requires *m/z* 389, found 390 [M+H]⁺.

3-(2-Benzyloxy-5-hydroxyphenyl)benzaldehyde (9a)—The title compound **9a** was prepared according to general procedure C using compound **8** (278 mg, 1.0 mmol), 3-formylphenylboronic acid (0.174 g, 1.2 mmol), Na₂CO₃ (0.53 g, 5 mmol), Pd(PPh₃)₄ (0.058 g, 0.05 mmol). The crude was purified by flash chromatography (cyclohexane/EtOAc 85:15) to afford **9a** as amber oil. 0.194 g, 64%. ¹H NMR (200 MHz, DMSO-*d*₆) δ 10.04 (s, 1H), 9.14 (s, 1H), 8.05 (t, *J* = 1.5 Hz, 1H), 7.88–7.81 (m, 2H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.33–7.22 (m, 5H), 7.06 (d, *J* = 9.0 Hz, 1H), 6.81–6.74 (m, 2H), 5.00 (s, 2H). MS (ESI) C₂₀H₁₆O₃ requires *m/z* 304, found 303 [M-H]⁻.

1-[3-(2-Benzyloxy-5-hydroxyphenyl)phenyl]ethanone (9b)—The title compound **9b** was prepared according to general procedure C using compound **8** (0.278 g, 1.0 mmol), 3-acetylphenylboronic acid (0.196 g, 1.2 mmol), Na₂CO₃ (0.53 g, 5 mmol), Pd(PPh₃)₄ (0.058

g, 0.05 mmol). The crude was purified by flash chromatography (cyclohexane/EtOAc 75:25 and then DCM/MeOH 99:1) to afford **9b** as white solid after crystallization from EtOH. 0.248 g, 78%. ¹H NMR (200 MHz, DMSO-*d*₆) δ 9.12 (br, 1H), 8.09 (t, *J* = 1.6 Hz, 1H), 7.89 (dt, *J* = 7.7 Hz, *J* = 1.4 Hz, 1H), 7.75 (dt, 7.7 Hz, *J* = 1.4 Hz, 1H), 7.54 (t, *J* = 7.7 Hz, *J* = 1.4 Hz, 1H), 7.33–7.28 (m, 5H), 7.06 (d, 8.8 Hz, 1H), 6.80–6.73 (m, 2H), 4.99 (s, 2H), 2.55 (s, 3H). MS (ESI) C₂₁H₁₈O₃ requires *m/z* 318, found 319 [M+H]⁺, 317 [M-H]⁻.

Cyclohexylcarbamic Acid 6-Benzyloxy-3'-formylbiphenyl-3-yl Ester (10a)—The title compound **10a** was prepared according to general procedure D using compound **9a** (0.304 g, 1.0 mmol), *c*-C₆H₁₁NCO (0.137 mg, 1.1 mmol), Et₃N (0.11 g, 0.154 mL, 1.1 mmol). The crude was purified by flash chromatography (cyclohexane/EtOAc 75:25) to afford **10a** as amber oil. 0.236 g, 55%. ¹H NMR (200 MHz, DMSO-*d*₆) δ 10.04 (s, 1H), 8.10 (t, *J* = 1.5 Hz 1H), 7.91–7.85 (m, 2H), 7.67–7.59 (m, 2H), 7.39–7.08 (m, 8H), 5.14 (s, 2H), 3.37–3.33 (m, 1H), 1.83–1.54 (m, 5H), 1.24–1.19 (m, 5H). MS (ESI) C₂₇H₂₇NO₄ requires *m/z* 429, found 430 [M+H]⁺.

Cyclohexylcarbamic Acid 3'-Acetyl-6-benzyloxybiphenyl-3-yl Ester (10b)—The title compound **10b** was prepared according to general procedure D using compound **9b** (0.318 g, 1.0 mmol), *c*-C₆H₁₁NCO (0.137 mg, 1.1 mmol), Et₃N (0.11 g, 0.154 mL, 1.1 mmol). The crude was purified by flash chromatography (cyclohexane/EtOAc 70:30) to afford **10b** as white solid, after crystallization from EtOH. 0.270 g, 61%. ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.12 (t, *J* = 1.5 Hz, 1H), 7.90 (dt, *J* = 8.0 Hz, *J* = 1.5 Hz, 1H), 7.79 (dt, *J* = 8.0 Hz, *J* = 1.5 Hz 1H), 7.64–7.52 (m, 2H), 7.40–7.20 (m, 6H), 7.12–7.07 (m, 2H), 5.13 (s, 2H), 3.38–3.31 (m, 1H), 2.55 (s, 3H), 1.83–1.53 (m, 5H), 1.23–1.06 (m, 5H). MS (ESI) C₂₈H₂₉NO₄ requires *m/z* 443, found 444 [M+H]⁺.

Cyclohexylcarbamic Acid 6-Hydroxy-3'-methylbiphenyl-3-yl Ester (11a)—The title compound **11a** was prepared according to general procedure E using compound **10a** (0.429 mg, 1 mmol) and 10% Pd/C (0.044 g). The crude was purified by flash chromatography (cyclohexane/EtOAc 40:60) to afford **11a** as a white solid, after crystallization from Et₂O. 0.061 g, 19%. ¹H NMR (200 MHz, chloroform-*d*) δ 7.39–7.18 (m, 4H), 7.01–6.84 (m, 3H), 5.60 (s, 1H), 4.95 (d, *J* = 8.0 Hz, 1H), 3.68–3.48 (m, 1H), 2.40 (s, 3H), 2.04–1.99 (d, *J* = 10.4 Hz, 2H), 1.78–1.61 (m, 3H), 1.48–1.11 (m, 5H). ¹³C NMR (50 MHz, chloroform-*d*) δ 154.2, 149.9, 144.3, 139.0, 136.47, 129.7, 129.1, 128.7, 128.6, 126.0, 123.0, 122.0, 116.3, 50.1, 33.3, 25.4, 24.7, 21.5. MS (ESI) C₂₀H₂₃NO₃ requires *m/z* 325, found 326 [M+H]⁺.

Cyclohexylcarbamic Acid 6-Hydroxy-3'-(1-hydroxyethyl)biphenyl-3-yl Ester (11b)—The title compound **11b** was prepared according to general procedure E using compound **10b** (0.443 g, 1.0 mmol) and 10% Pd/C (0.044 g). The crude was purified by flash chromatography (cyclohexane/EtOAc 40:60) to afford **11b** as a white amorphous solid. 0.176 g, 50%. ¹H NMR (200 MHz, chloroform-*d*) δ 7.37–7.27 (m, 4H), 6.96–6.61 (m, 3H), 5.11 (d, *J* = 8.0 Hz, 1H), 4.81–4.71 (m, 1H), 3.55–3.51 (m, 1H), 2.82 (br, 1H), 2.05–1.96 (m, 2H), 1.69–1.59 (m, 3H), 1.42 (d, *J* = 6.4 Hz, 3H), 1.33–1.15 (m, 6H). ¹³C NMR (50 MHz, chloroform-*d*) δ 181.4, 154.7, 150.4, 146.1, 144.0, 137.2, 128.7, 128.1, 126.3, 124.6,

123.2, 121.8, 116.8, 70.2, 50.2, 33.2, 25.4, 25.0, 24.7. MS (ESI) $C_{21}H_{25}NO_4$ requires m/z 355, found 354 $[M-H]^-$, 356 $[M+H]^+$.

Cyclohexylcarbamic Acid 6-Hydroxy-3'-hydroxymethylbiphenyl-3-yl Ester

(11c)—The title compound **11c** was prepared according to general procedure E using compound **10a** (0.429 g, 1 mmol) and 10% Pd/C (0.044 g). The crude was purified by flash chromatography (cyclohexane/EtOAc 40:60) to afford **11c** as a white amorphous solid. 0.112 g, 30%. 1H NMR (200 MHz, chloroform-*d*) δ 7.44–7.34 (m, 4H), 7.00–6.83 (m, 3H), 5.60 (s, 1H), 4.93 (d, $J = 8.2$ Hz, 1H), 4.69 (s, 2H), 3.57–3.43 (m, 1H), 2.05–1.97 (m, 3H), 1.77–1.70 (m, 3H), 1.42–1.06 (m, 4H). ^{13}C NMR (50 MHz, chloroform-*d*) δ 154.5, 150.2, 144.1, 141.5, 137.1, 129.0, 128.6, 128.2, 127.7, 126.3, 123.2, 121.9, 116.7, 66.0, 50.2, 33.2, 25.4, 24.7. MS (ESI) $C_{20}H_{23}NO_4$ requires m/z 341, found 342 $[M+H]^+$.

3-Bromo-4-methoxyphenol (13)—To a solution of **12** (214 mg, 1 mmol) in DCM (5 mL), *m*-CPBA (0.173 g, 1 mmol) was added. The mixture was stirred for 72 h at 40 °C, and then washed with a saturated aqueous $Na_2S_2O_3$ solution (5 mL) and with a saturated aqueous $NaHCO_3$ solution (5 mL). The combined organic layers were dried (Na_2SO_4). After evaporation of the solvent, the residue was dissolved in EtOH (5 mL), $NaOCH_3$ (0.108 g, 2 mmol) was added and the mixture was stirred for 1 h at room temperature, concentrated in vacuo and acidified with 2 N HCl (5 mL), and extracted with DCM (5 \times 3 mL). The combined organic layers were dried (Na_2SO_4). After evaporation of the solvent, the residue was purified by flash chromatography (cyclohexane/DCM = 20:80) to afford **13**. 0.121 g, 60%. MS and 1H NMR are according to the literature.³⁵

3-(5-Hydroxy-2-methoxyphenyl)benzamide (14)—The title compound **14** was prepared according to general procedure C using compound **13** (0.202 g, 1 mmol), 3'-carbamoylphenylboronic acid (0.198 g, 1.2 mmol), Na_2CO_3 (0.52 g, 5 mmol), and $Pd(PPh_3)_4$ (0.020 mg). The crude was purified by flash chromatography (DCM/MeOH = 94:6) to afford **14** as a white solid. 0.197 g, 81%. 1H NMR (200 MHz, DMSO-*d*₆) δ 9.10 (s, 1H), 8.03 (s, 1H), 7.93–7.91 (m, 1H), 7.82–7.78 (m, 1H), 7.61–7.57 (m, 1H), 7.49–7.45 (m, 1H), 7.41–7.39 (m, 1H), 6.96–6.91 (m, 1H), 6.77–6.71 (m, 2H), 3.65 (s, 3H). MS (ESI) $C_{14}H_{13}NO_3$ requires m/z 243, found 242 $[M-H]^-$.

Cyclohexylcarbamic Acid 3'-Carbamoyl-6-methoxybiphenyl-3-yl Ester (15)

The title compound **15** was prepared according to general procedure D using compound **14** (0.243 g, 1.0 mmol), *c*- $C_6H_{11}NCO$ (0.137 mg, 1.1 mmol), Et_3N (0.11 g, 0.154 mL, 1.1 mmol). The crude was purified by flash chromatography (cyclohexane/EtOAc 30:70) to afford **15** as a white solid. 0.284 g, 77%. 1H NMR (200 MHz, chloroform-*d*) δ 7.93–7.91 (m, 1H), 7.82–7.77 (m, 1H), 7.72–7.68 (m, 1H), 7.52–7.44 (m, 1H), 7.14–7.07 (m, 2H), 6.97–6.92 (m, 1H), 6.26–5.73 (m, 2H), 4.98–4.82 (m, 1H), 3.80 (s, 3H), 3.58–3.54 (m, 1H), 1.13–2.04 (m, 10H). ^{13}C NMR (50 MHz, chloroform-*d*) δ 169.4, 154.1, 153.7, 144.6, 138.2, 133.2, 133.1, 130.1, 128.3, 126.3, 124.0, 121.9, 111.8, 56.0, 50.2, 33.3, 25.4, 24.7. MS (ESI) $C_{21}H_{24}N_2O_4$ requires m/z 368, found 369 $[M+H]^+$.

2-(2-Bromo-4-fluorophenyl)-1,3-dioxolane (17)²³—To a solution of **16** (4.0 g, 19.7 mmol) in dry toluene (30 mL) ethylene glycol (5.56 mL, 98.5 mmol) and *p*-TSA (187 mg, 1 mmol) were added and the reaction mixture was heated at reflux for 12h. The mixture was cooled down to room temperature and then poured into saturated aqueous NH₄Cl solution (50 mL). The two phases were separated and the organic solution was washed with brine and dried (Na₂SO₄). Evaporation of the solvent gave **17** as light yellow oil that was used in the next step without further purification. 4.5 g. ¹H NMR (400 MHz, chloroform-*d*) δ 7.62 (dd, *J* = 8.3, 6.1 Hz, 1H), 7.34 (dd, *J* = 8.3, 2.6 Hz, 1H), 7.08 (td, *J* = 8.3, 2.6 Hz, 1H), 6.07 (s, 1H), 4.46–3.85 (m, 4H).

4-Benzyloxy-2-bromobenzaldehyde (18)—To a solution of **17** (4.0 g, 16.19 mmol) in dry dioxane (60 mL), BnOH (6.27 mL, 64.78 mmol) and *t*-BuOK (7.27 g, 64.78 mmol) were added and then the mixture was heated at 85 °C for 1 h. The mixture was cooled down to room temperature and then poured into H₂O (150 mL) and EtOAc (200 mL) and the two phases were separated. To the organic solution 2 N HCl (150 mL) was added and stirring was continued for 2 h at room temperature. The two phases were then separated and the organic layer was dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (0 to 10% EtOAc in cyclohexane) to yield **18** as a white solid. 3.53 g, 75%. ¹H NMR (400 MHz, chloroform-*d*) δ 10.25 (d, *J* = 0.8 Hz, 1H), 7.92 (d, *J* = 8.8 Hz, 1H), 7.48–7.34 (m, 5H), 7.25 (d, *J* = 2.5 Hz, 1H), 7.03 (dd, *J* = 8.8, 2.5 Hz, 1H), 5.16 (s, 2H). MS (ESI): no ionization.

3-(5-Benzyloxy-2-formylphenyl)benzamide (19)—To a solution of **18** (1.41g, 4.85 mmol) in ethyleneglycol monomethyl ether (EGME) (30 mL), H₂O was slowly added (8 mL) followed by the addition of K₂CO₃ (1.34 g, 9.69 mmol), 3-carbamoylbenzeneboronic acid (1.2 g, 7.27 mmol), and Pd(OAc)₂ (10.8 mg, 0.049 mmol). The mixture was stirred at room temperature for 40 min until the mixture became dark and a precipitate was formed. H₂O (40 mL) was then added and the solid was filtered and washed with H₂O (15 mL) to afford **19** as a whitish solid. 1.53 g, 95%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.74 (s, 1H), 8.08 (bs, 1H), 8.00–7.92 (m, 3H), 7.65–7.55 (m, 2H), 7.55–7.33 (m, 6H), 7.25 (dd, *J* = 8.6, 2.5 Hz, 1H), 7.15 (d, *J* = 2.5 Hz, 1H), 5.30 (s, 2H). MS (ESI) C₂₁H₁₇NO₃ requires *m/z* 331, found 332 [M+H]⁺

3-[5-Benzyloxy-2-hydroxymethylphenyl]benzamide (20)—To a suspension of **19** (1.6 g, 4.83 mmol) in EtOH (20 mL), NaBH₄ (365 mg, 9.67 mmol) was added slowly at 0 °C and the mixture was stirred for 2 h. The reaction was diluted with DCM (50 mL) and quenched by the addition of saturated aqueous Na₂CO₃ solution (20 mL) and H₂O (20 mL) to afford a precipitate that was filtered to give **20** as a grayish solid. 1.3 g, 81%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.00 (bs, 1H), 7.95–7.83 (m, 2H), 7.67–7.27 (m, 9H), 7.06 (dd, *J* = 8.5, 2.7 Hz, 1H), 6.92 (d, *J* = 2.7 Hz, 1H), 5.16 (s, 2H), 5.02 (t, *J* = 5.2 Hz, 1H), 4.32 (d, *J* = 5.2 Hz, 2H). MS (ESI) C₂₁H₁₉NO₃ requires *m/z* 333, found 316 [M-H₂O+H]⁺

Cyclohexylcarbamic Acid 3'-Carbamoyl-6-hydroxymethylbiphenyl-3-yl Ester (21)—A suspension of **20** (1.3 g, 3.89 mmol) in MeOH (80 mL) under N₂ atmosphere was heated at reflux until complete dissolution and then 10% Pd/C (700 mg) were rapidly added

followed by the addition of γ -terpinene (6.2 mL, 38.9 mmol). The mixture was heated at reflux for additional 1 h then was cooled down to room temperature, filtered through Celite and washed with MeOH (15 mL). The filtrate was concentrated to dryness affording a colorless solid, which was dissolved in a 1:1 mixture of CH₃CN/EtOH (20 mL). To this solution, Et₃N (0.32 mL, 2.35 mmol) and *c*-C₆H₁₁NCO (0.5 mL, 3.89 mmol) were added and the mixture was stirred at room temperature for 12h. The reaction was quenched by the addition of EtOAc (80 mL) and 2 N HCl (80 mL) that, after vigorously stirring, were then separated. The aqueous solution was extracted with EtOAc (40 mL) and then the combined organic layers were dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (100% EtOAc) and then crystallized from EtOH/H₂O to afford **21** as a white solid. 630 mg, 44%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.03 (bs, 1H), 7.94–7.80 (m, 2H), 7.71 (d, *J* = 7.9 Hz, 1H), 7.64–7.47 (m, 3H), 7.39 (bs, 1H), 7.13 (dd, *J* = 8.4, 2.5 Hz, 1H), 6.99 (d, *J* = 2.5 Hz, 1H), 5.15 (t, *J* = 5.1 Hz, 1H), 4.38 (d, *J* = 5.1 Hz, 2H), 3.42–3.22 (m, 1H), 2.03–1.49 (m, 5H), 1.37–0.99 (m, 5H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 168.2, 153.9, 150.3, 140.9, 140.0, 136.3, 134.9, 132.2, 129.7, 128.6, 128.3, 127.0, 122.9, 121.3, 60.8, 50.3, 33.0, 25.6, 25.0. MS (ESI) *m/z* C₂₁H₂₄N₂O₄ requires *m/z* 368, found 386 [M+NH₄]⁺, 737 [2M+H]⁺.

1-(2-Bromo-4-methoxyphenyl)ethanone (23)—To a suspension of ZrCl₄ (37.63 g, 0.16 mol) in dry DCM (500 mL), **22** (16.78 mL, 0.17 mol) was added at -10 °C under N₂ atmosphere followed by the addition of AcCl in 15 mL of DCM dropwise. The orange turbid solution was stirred at -10 °C for 1 h, then the reaction mixture was carefully poured into a 3 L flask containing of 2 N HCl (500 mL) and of DCM (150 mL), and stirred for 40 min. The phases were separated and the milky organic phase dried (Na₂SO₄). The residue was dissolved in MTBE (300 mL) and the mixture was filtered through a pad of Celite to give a clear colorless solution. After evaporation of the solvent, the residue was purified by flash chromatography (0 to 20% EtOAc in cyclohexane) to afford **23** as a light yellow oil. 17 g, 55%. ¹H NMR (400 MHz, chloroform-*d*) δ 7.61 (d, *J* = 8.7 Hz, 1H), 7.18 (d, *J* = 2.5 Hz, 1H), 6.90 (dd, *J* = 8.7, 2.5 Hz, 1H), 3.87 (s, 3H), 2.65 (s, 3H). MS (ESI) C₉H₉BrO₂ requires *m/z* 228, 230, found 229, 231 [M+H]⁺.

2-Bromo-4-methoxybenzoic acid (24)—To a suspension of *t*-BuONa (2.77 g, 28.8 mmol) in dry THF (50 mL), diethyl oxalate (6.06 mL, 39.3 mmol) was carefully added under N₂ atmosphere and the yellow reaction mixture was stirred at room temperature for 30 min. A solution of **23** (3.0 g, 13.10 mmol) in dry THF (15 mL) was then added dropwise and the mixture was stirred at room temperature for additional 30 min. The reaction mixture was carefully poured into a mixture of 1 N HCl (200 mL) and EtOAc (200 mL), then the phases were separated and the organic layer was concentrated in vacuo to give a yellow oil. It was dissolved in a 5:3 mixture of acetone/H₂O (160 mL) then NaHCO₃ was added (11.0 g, 131.0 mmol) and cooled down to 0 °C. To this mixture, Oxone® (20.1 g, 32.8 mmol) was added very carefully and an evolution of gas was immediately observed. The mixture was stirred at 0 °C for 2 h then the solids were filtered off. To the filtrate, solid Na₂S₂O₃ was added under stirring until disappearance of oxidant (KI solution test). The mixture was concentrated to remove residual acetone and then 2N HCl (20 mL) was added until acidic pH while a white precipitate immediately was formed which was filtered and washed with H₂O (20 mL) to

afford **24** as a white solid. 2.3 g, 77%. $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 13.00 (bs, 1H), 7.82 (d, $J = 8.7$ Hz, 1H), 7.27 (d, $J = 2.5$ Hz, 1H), 7.04 (dd, $J = 8.7, 2.5$ Hz, 1H), 3.84 (s, 3H). MS (ESI) $\text{C}_8\text{H}_7\text{BrO}_3$ requires m/z 230, 232, found 231, 233 $[\text{M}+\text{H}]^+$.

2-Bromo-4-hydroxybenzoic acid (25)—To a suspension of **24** (3.0 g, 13.0 mmol) in dry DCM (50 mL) BBr_3 (39 mL, 1 M solution in DCM) was added dropwise at 0°C under N_2 atmosphere for 30 min until complete dissolution and then left under stirring at room temperature for 12h while a precipitate was formed. The reaction mixture was quenched at 0°C by a careful addition of 5 N NaOH (10 mL) until pH >11. H_2O (50 mL) and DCM (50 mL) were then added and the mixture was stirred for additional 2 h. The two phases were separated and the organic layer was washed with H_2O (30 mL). The aqueous phase was carefully acidified with 37% HCl until pH 1. NaCl (10 g) was added portionwise and a white precipitate immediately was formed. The mixture was stirred at 0°C for 1.5 h and then filtered to give **25** as a white solid. 1.7 g, 61%. $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 12.78 (bs, 1H), 10.54 (bs, 1H), 7.75 (d, $J = 8.6$ Hz, 1H), 7.08 (d, $J = 2.4$ Hz, 1H), 6.84 (dd, $J = 8.6, 2.4$ Hz, 1H). MS (ESI) $\text{C}_7\text{H}_5\text{BrO}_3$ requires m/z 216, 217, found 215, 217 $[\text{M}-\text{H}]^-$.

Benzyl 2-bromo-4-hydroxybenzoate (26)—To a solution of **25** (3.0 g, 13.8 mmol) in DMF (30 mL), KHCO_3 (2.1 g, 20.7 mmol) was added under vigorous stirring followed by the addition of BnBr (1.47 mL, 12.44 mmol). The yellow mixture was stirred for 12h at room temperature and then poured into a mixture of 1 N HCl (200 mL) and MTBE (200 mL) under stirring. The two phases were separated and the organic layer was dried (Na_2SO_4). Evaporation of solvent gave **26** as a yellow oil that was used in the next step without further purification. 4.1 g. $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 10.69 (s, 1H), 7.80 (d, $J = 8.7$ Hz, 1H), 7.51–7.45 (m, 2H), 7.45–7.33 (m, 3H), 7.12 (d, $J = 2.4$ Hz, 1H), 6.87 (dd, $J = 8.7, 2.4$ Hz, 1H), 5.30 (s, 2H). MS (ESI) $\text{C}_{14}\text{H}_{11}\text{BrO}_3$ requires m/z 306, 308, found 307, 309 $[\text{M}+\text{H}]^+$.

Benzyl 2-(3-carbamoylphenyl)-4-hydroxybenzoate (27)—To a solution of **26** (4.2 g, 13.68 mmol) in dioxane (100 mL), H_2O (80 mL) was added followed by the addition of Na_2CO_3 (2.9 g, 27.36 mmol) and 3-carbamoylphenylboronic acid (3.4 g, 20.52 mmol). To this solution, PdCl_2dppf (500 mg, 0.034 mmol) was added and then the mixture was heated at 90°C for 1.5 h under N_2 atmosphere. The mixture was cooled down to room temperature and then poured into 1 N HCl (200 mL) and EtOAc (200 mL) under stirring. After 30 min, the two phases were separated and the aqueous phase was extracted with EtOAc (100 mL). The combined organic layers were dried (Na_2SO_4). After evaporation of the solvent, the residue was purified by flash chromatography (40 to 100% EtOAc in DCM) to afford **27** as a whitish solid. 2.73 g, 57%. $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 10.37 (bs, 1H), 8.02 (bs, 1H), 7.92–7.76 (m, 3H), 7.51–7.33 (m, 3H), 7.30–7.23 (m, 3H), 7.11–7.01 (m, 2H), 6.89 (dd, $J = 8.6, 2.5$ Hz, 1H), 6.75 (d, $J = 2.5$ Hz, 1H), 5.02 (s, 2H). MS (ESI) $\text{C}_{21}\text{H}_{17}\text{NO}_4$ requires m/z 347, found 348 $[\text{M}+\text{H}]^+$.

Cyclohexylcarbamic Acid 6-Benzyloxycarbonyl-3'-carbamoylbiphenyl-3-yl Ester (28)—A suspension of **27** (2.7g, 7.78 mmol) in dioxane (100 mL) was heated at 50°C until a yellow solution was formed. The reaction mixture was cooled down to room

temperature and DMAP (250 mg, 2.04 mmol) and *c*-C₆H₁₁CNO (1.2 mL, 9.33 mmol) were added and the mixture was heated at 45 °C for 12h, then cooled down to room temperature and poured into 1 N HCl (200 mL) and EtOAc (200 mL) under stirring. The two phases were separated and the aqueous layer was extracted with EtOAc (100 mL). The combined organic layers were dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (20 to 50% EtOAc in DCM) to afford **28** as a white fluffy solid. 2.8 g, 76%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.05 (bs, 1H), 7.95–7.82 (m, 4H), 7.52–7.36 (m, 2H), 7.33–7.24 (m, 4H), 7.21 (d, *J* = 2.4 Hz, 1H), 7.13–7.00 (m, 2H), 5.08 (s, 2H), 3.32 (m, 1H), 1.91–1.48 (m, 5H), 1.38–1.01 (m, 6H). MS (ESI) C₂₈H₂₈N₂O₅ requires *m/z* 472, found 473 [M+H]⁺.

Cyclohexylcarbamic Acid 3'-Carbamoyl-6-carboxybiphenyl-3-yl Ester (29)—To a solution of **28** (2.7 g, 5.72 mmol) in dioxane (200 mL), cyclohexene (50 mL) and 10% Pd/C (2 g) were added. The mixture was heated at 85 °C for 2 h, then was cooled down to room temperature, added of activated carbon (2 g), and filtered through a pad of Celite. Evaporation of solvent gave **29** as white solid. 960 mg, 44%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.61 (bs, 1H), 8.04 (bs, 1H), 7.95–7.73 (m, 4H), 7.55–7.43 (m, 2H), 7.38 (s, 1H), 7.23 (dd, *J* = 8.5, 2.4 Hz, 1H), 7.15 (d, *J* = 2.4 Hz, 1H), 3.33 (m, 1H), 2.00–1.48 (m, 5H), 1.39–0.99 (m, 5H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 169.0, 168.6, 153.3, 153.3, 142.9, 140.7, 134.6, 131.6, 131.5, 128.7, 128.4, 127.8, 127.0, 124.0, 121.1, 50.4, 32.9, 25.6, 25.0. MS (ESI) C₂₁H₂₂N₂O₅ requires *m/z* 382, found 383 [M+H]⁺.

Ammonium Cyclohexylcarbamic Acid 3'-Carbamoyl-6-sulfatebiphenyl-3-yl Ester (30)—To a suspension of **3** (200 mg, 0.62 mmol) in dry DCM (5 mL), SO₃-DMF complex (593 mg, 3.73 mmol) was added. After stirring at room temperature for 1 h, pyridine (2 mL) was added and the reaction mixture was concentrated in vacuo to give a colorless oil that was purified by preparative HPLC (column, C18), using the following eluent conditions: 20% B for 0.5 min then 20% to 60% B in 7 min; R_t: 4.5 min to afford **30** as a white solid. 125 mg, 44%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.08–8.01 (m, 1H), 7.91 (bs, 1H), 7.87–7.76 (m, 2H), 7.69 (d, *J* = 7.9 Hz, 1H), 7.63 (d, *J* = 8.8 Hz, 1H), 7.48 (t, *J* = 7.7 Hz, 1H), 7.36 (bs, 1H), 7.11 (d, *J* = 2.9 Hz, 1H), 7.05 (dd, *J* = 8.9, 2.9 Hz, 1H), 3.50 (bs, 4H), 3.41–3.22 (m, 1H), 1.89–1.78 (m, 2H), 1.78–1.66 (m, 2H), 1.63–1.49 (m, 1H), 1.43–0.95 (m, 5H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 168.6, 154.1, 147.8, 147.1, 137.7, 134.7, 133.2, 132.7, 128.6, 128.3, 126.7, 123.4, 122.3, 121.9, 50.2, 33.0, 25.6, 25.0. MS (ESI) C₂₀H₂₂N₂O₇S requires *m/z* 434, found 433 [M-H]⁻.

1,3-Dibenzoyloxy-5-bromobenzene (32)—To a solution of *t*-BuONa (19.9 g, 207.3 mmol) and BnOH (21.3 mL, 207.3 mmol) in dry DMF (200 mL), 1-bromo-3,5-difluorobenzene **31** (4.8 mL, 41.5 mmol) was added under N₂ atmosphere. The reaction mixture was stirred at 90 °C for 3 h. The dark yellow mixture was cooled down to room temperature and, under stirring, slowly transferred in a 3 L flask containing H₂O (600 mL) and of MTBE (500 mL). After 30 min, the organic phase was separated, washed with H₂O (400 mL) and dried (Na₂SO₄). Evaporation of the solvent gave **32** as yellow oil that crystallized after 12h upon cooling at -19 °C. The solid was treated with 180 mL of MeOH then filtered and washed with cold MeOH (30 mL). 11 g, 72%. ¹H NMR (400 MHz,

chloroform-*d*) δ 7.52–7.31 (m, 10H), 6.80 (d, J = 2.2 Hz, 2H), 6.57 (t, J = 2.2 Hz, 1H), 5.03 (s, 4H). MS (ESI) $C_{20}H_{17}BrO_2$ requires m/z 368, found 367 (M-H)⁻.

3-(3,5-Dibenzyloxyphenyl)benzamide (33)—To a solution of **32** (11.0 g, 29.8 mmol) in EGME (152 mL), H₂O (54 mL) was added dropwise, followed by the addition of K₂CO₃ (8.2 g, 59.6 mmol), 3-carbamoylphenylboronic acid (7.4 g, 44.7 mmol), and Pd(OAc)₂ (80.3 mg 0.36 mmol). The reaction mixture was stirred at 60 °C for 20 min. Then, H₂O (100 mL) were added and a precipitate was formed which was filtered and washed with cold H₂O (50 mL). The solid was recrystallized from MeOH/THF (2.5:1, 350 mL) to give **33** as a light grey solid. 8.5 g, 70%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.15 (t, J = 1.8 Hz, 1H), 8.12 (bs, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.61–7.30 (m, 12H), 7.00 (d, J = 2.2 Hz, 2H), 6.73 (t, J = 2.2 Hz, 1H), 5.19 (s, 4H). MS (ESI) $C_{27}H_{23}NO_3$ requires m/z 409, found 410 (M+H)⁺.

3-(3,5-Dihydroxyphenyl)benzamide (34)—To a suspension of **33** (8.5 g, 20.8 mmol) in dioxane (260 mL), cyclohexene (80 mL) was added and the mixture was heated at 50 °C for 15 min until complete dissolution, cooled down to room temperature and 10% Pd/C (2 g) was added. The reaction mixture was heated at 80 °C for 2 h and an additional amount of 10% Pd/C (2 g) was then added. After additional 2h, the mixture was cooled down to room temperature and filtered through a pad of Celite, washed with dioxane (100 mL) and of absolute EtOH (100 mL). The clear solution was concentrated in vacuo to afford **34** as a light yellow solid. 4.8 g, 100%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.38 (s, 2H), 8.10 (bs, 1H), 8.07–8.03 (m, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.50 (t, J = 7.7 Hz, 1H), 7.38 (bs, 1H), 6.55 (d, J = 2.1 Hz, 2H), 6.27 (t, J = 2.1 Hz, 1H). MS (ESI) $C_{13}H_{11}NO_3$ requires m/z 229, found 230 (M+H)⁺.

Cyclohexylcarbamic Acid 3'-Carbamoyl-5-hydroxybiphenyl-3-yl Ester (35)—To a solution of **34** (2.6 g, 11.4 mmol) in dry DMF (30 mL), CuCl (1.1 g, 11.4 mmol) was added and the reaction mixture turned rapidly to a brown color. *c*-C₆H₁₁CNO (1.45 mL, 11.4 mmol) was then added and the mixture was stirred at room temperature for 30 min. To this solution, a mixture of 3% aqueous citric acid solution (200 mL) and EtOAc (100 mL) were then added. The organic phase was separated and dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (50 to 100% EtOAc in cyclohexane) to afford **35** as a white solid. The solid was dissolved in a 6.5:2.0:1.5 mixture of H₂O: acetone: EtOH (75 mL). To this solution, H₂O (30 mL) were then added and a precipitate was formed which was filtered to afford **35** as a white solid. 1.17 g, 29%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.86 (s, 1H), 8.13 (bs, 1H), 8.11– 8.09 (m, 1H), 7.86 (d, J = 7.7 Hz, 1H), 7.75 (d, J = 7.7 Hz, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.53 (t, J = 7.7 Hz, 1H), 7.41 (bs, 1H), 6.95 (t, J = 1.9 Hz, 1H), 6.89 (t, J = 1.9 Hz, 1H), 6.53 (d, J = 1.9 Hz, 1H), 3.46–3.32 (m, 1H), 1.99–1.46 (m, 6H), 1.46–0.99 (m, 4H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 168.2, 158.9, 153.8, 153.0, 141.8, 139.9, 135.4, 129.7, 129.4, 127.4, 126.0, 111.4, 110.8, 108.8, 50.2, 33.0, 25.6, 25.0. MS (ESI) $C_{20}H_{22}N_2O_4$ requires m/z 354, found 355 (M+H)⁺.

3,5-Dimethoxyphenyl trifluoromethanesulfonate (38)—To a solution of **37** (0.154 g, 1.0 mmol) in DCM (3 mL), DMAP (0.183 g, 1.5 mmol) and (CF₃SO₂)₂O (0.366 g, 0.22

mL, 1.3 mmol) were added at 0 °C. The mixture was stirred for 15 min at room temperature and concentrated. The residue was purified by flash chromatography (cyclohexane/EtOAc 3:7) to afford **38**, which was used directly in the next step without characterization.

3-(3,5-Dimethoxyphenyl)benzamide (39)—To a solution of (*n*-BuN)₄Br (0.332 g, 1.0 mmol) and Na₂CO₃ (0.265 g, 2.5 mmol) in EtOH (5 mL), **38** (0.286, 1.0 mmol), 3-carbamoylphenylboronic acid (0.165 g, 1.0 mmol) and PdCl₂ (18 mg, 0.1 mmol) were added. The mixture was refluxed for 12 h, filtered on a plug of Celite, acidified with 2 N HCl (5 mL), and extracted with EtOAc (5×3 mL). The combined organic layers were dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (DCM/MeOH 95:5 and then cyclohexane/EtOAc 30:70) gave **39** as a white solid. 0.115 g, 45%. ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.12 (t, *J* = 1.6 Hz, 1H), 8.08 (br, 1H), 7.88–7.80 (m, 2H), 7.52 (t, *J* = 7.7 Hz, 1H), 7.39 (br, 1H), 6.85 (d, *J* = 2.4 Hz, 2H), 6.53 (t, *J* = 2.2 Hz, 1H), 3.82 (s, 6H). MS (ESI) C₁₅H₁₅NO₃ requires *m/z* 257, found 258 [M+H]⁺.

3-(3-Hydroxy-5-methoxyphenyl)benzamide (40)—To a solution of **39** (0.257 g, 1.0 mmol) in dry DCM (9 mL), BBr₃ (5.0 mL, 1.0 M solution in DCM, 5 mmol) was added at 0 °C. The mixture was stirred for 30 min at room temperature, then H₂O (5 mL) was added and the mixture was extracted with DCM (5 mL) and EtOAc (5×2 mL). The combined organic layers were dried (Na₂SO₄). After evaporation of the solvent, the residue was purified by flash chromatography (DCM/MeOH 95:5) to afford **40** as a white amorphous solid. 97 mg, 40%. ¹H NMR (200 MHz, DMSO-*d*₆) δ 7.87–7.81 (m, 3H), 7.59–7.42 (m, 4H), 5.80 (br, 3H), 1.57 (s, 3H). MS (ESI) C₁₄H₁₃NO₃ requires *m/z* 243, found 244 [M+H]⁺.

Cyclohexylcarbamic Acid 3'-Carbamoyl-5-methoxybiphenyl-3-yl Ester (41)—To a solution of **40** (0.243 g, 1 mmol) in CH₃CN (25 mL), *c*-C₆H₁₁NCO (0.137 mg, 1.1 mmol), Et₃N (0.11 g, 0.154 mL, 1.1 mmol) were added. The mixture was refluxed for 2 h and concentrated. The residue was purified by flash chromatography (DCM/EtOAc 70:30) to afford **41** as a white solid after crystallization from EtOAc/petroleum ether. 0.240 g, 65%. ¹H NMR (200 MHz, DMSO-*d*₆) δ 8.14–8.09 (m, 2H), 7.80–7.79 (m, 2H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.53 (t, *J* = 7.7 Hz, 1H), 7.39 (s, 1H), 7.13 (m, 1H), 7.05 (t, *J* = 1.7 Hz, 1H), 6.71 (t, *J* = 2.1 Hz, 1H), 3.84 (s, 3H), 3.41–3.30 (m, 1H), 1.85–1.55 (m, 5H), 1.25–1.21 (m, 5H). ¹³C NMR (50 MHz, DMSO-*d*₆) δ 168.2, 160.9, 153.7, 153.1, 141.8, 139.7, 135.4, 129.9, 129.4, 127.6, 126.1, 113.1, 109.6, 107.7, 56.0, 50.3, 33.0, 25.6, 25.0. MS (ESI) C₂₁H₂₄N₂O₄ requires *m/z* 368, found 369 [M+H]⁺.

Acknowledgments

The authors wish to thank Sine Mandrup Bertozzi for reverse phase HPLC purifications, Luca Goldoni for NMR technical support, Silvia Venzano for compounds handling and Masih A. Babagoli for experimental assistance.

Funding Sources

Funding by NIH grant DA-012423 (to D.P.) is gratefully acknowledged. Universities of Parma and Urbino “Carlo Bo” also supported the work.

ABBREVIATIONS

FAAH	fatty-acid amide hydrolase
ABCG2	ATP-binding cassette transporter G2
BBB	blood-brain barrier
CB₁	cannabinoid type-1 receptor
CNS	central nervous system
ED₅₀	median effective dose
IC₅₀	median inhibitory dose
Oxone®	potassium peroxymonosulfate
PSA	polar surface area
PST	phenol sulfotransferase
SAR	structure-activity relationship
dppf	1,1'-bis(diphenylphosphino)ferrocene
EGME	ethyleneglycol monomethyl ether
MTBE	methyl <i>tert</i> -butyl ether
SiO₂	silica gel
TBSCI	<i>tert</i> -butyldimethylchlorosilane
TIPSCI	triisopropylchlorosilane

REFERENCES

1. Mechoulam R, Parker LA. The endocannabinoid system and the brain. *Annu Rev Psychol.* 2013; 64:21–47. [PubMed: 22804774]
2. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature.* 1994; 372:686–691. [PubMed: 7990962]
3. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. *Nature.* 1997; 388:773–778. [PubMed: 9285589]
4. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). *CNS Drug Rev.* 2006; 12:21–38. [PubMed: 16834756]
5. Bisogno T, Maccarrone M. Latest advances in the discovery of fatty acid amide hydrolase inhibitors. *Expert Opin Drug Discov.* 2013; 8:509–522. [PubMed: 23488865]
6. Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? *Trends Pharmacol Sci.* 2009; 30:1–7. [PubMed: 19042036]
7. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat Neurosci.* 2007; 10:870–879. [PubMed: 17558404]
8. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G. Hepatic CB1 receptor is required for development of diet-induced

- steatosis, dyslipidemia, and insulin and leptin resistance in mice. *J Clin Invest.* 2008; 118:3160–3169. [PubMed: 18677409]
9. LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Stella N, Xu C, Tarzia G, Piomelli D. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. *Bioorg Med Chem Lett.* 2009; 19:639–643. [PubMed: 19128970]
 10. Plowright AT, Nilsson K, Antonsson M, Amin K, Broddefalk J, Jensen J, Lehmann A, Jin S, St-Onge S, Tomaszewski MJ, Tremblay M, Walpole C, Wei Z, Yang H, Ulander J. Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease. *J Med Chem.* 2013; 56:220–240. [PubMed: 23227781]
 11. Fulp A, Bortoff K, Seltzman H, Zhang Y, Mathews J, Snyder R, Fennell T, Maitra R. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity. *J Med Chem.* 2012; 55:2820–2834. [PubMed: 22372835]
 12. Wittgen HG, Greupink R, van den Heuvel JJ, van den Broek PH, Dinter-Heidorn H, Koenderink JB, Russel FG. Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists. *Mol Pharm.* 2012; 9:1351–1360. [PubMed: 22428727]
 13. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. *Nat Neurosci.* 2010; 13:1265–1270. [PubMed: 20852626]
 14. Moreno-Sanz G, Barrera B, Guijarro A, d'Elia I, Otero JA, Alvarez AI, Bandiera T, Merino G, Piomelli D. The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. *Pharmacol Res.* 2011; 64:359–363. [PubMed: 21767647]
 15. Moreno-Sanz G, Sasso O, Guijarro A, Oluyemi O, Bertorelli R, Reggiani A, Piomelli D. Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier. *Br J Pharmacol.* 2012; 167:1620–1628. [PubMed: 22774772]
 16. Robey RW, Ierano C, Zhan Z, Bates SE. The challenge of exploiting ABCG2 in the clinic. *Curr Pharm Biotechnol.* 2011; 12:595–608. [PubMed: 21118093]
 17. Vacondio F, Silva C, Lodola A, Fioni A, Rivara S, Duranti A, Tontini A, Sanchini S, Clapper JR, Piomelli D, Mor M, Tarzia G. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. *ChemMedChem.* 2009; 4:1495–1504. [PubMed: 19554599]
 18. Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, Sanchini S, Tarzia G, Mor M, Piomelli D. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. *ChemMedChem.* 2009; 4:1505–1513. [PubMed: 19637155]
 19. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. *Mol Cancer Ther.* 2002; 1:417–425. [PubMed: 12477054]
 20. Fiorelli CS, R. Piomelli D, Bandiera T. Development of a Multigram Synthesis of URB937, a Peripherally Restricted FAAH Inhibitor. *Org Process Res Dev.* 2013; 17:359–367.
 21. Sasso O, Bertorelli R, Bandiera T, Scarpelli R, Colombano G, Armirotti A, Moreno-Sanz G, Reggiani A, Piomelli D. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. *Pharmacol Res.* 2012; 65:553–563. [PubMed: 22420940]
 22. Kürti, L.; Czakó, B. *Strategic Applications of Named Reactions in Organic Synthesis.* Elsevier Inc.; 2005. p. 118-119.
 23. Ding D, Zhao Y, Meng Q, Xie D, Nare B, Chen D, Bacchi CJ, Yarlett N, Zhang Y-K, Hernandez V, Hernandez V, Xia Y, Freund Y, Abdulla M, Ang K-H, Ratnam J, McKerrow JH, Jacobs RT, Zhou H, Plattner JJ. Discovery of novel benzoxaborole-based potent antitrypanosomal agents. *ACS Med. Chem. Lett.* 2010; 1:165–169. [PubMed: 24900190]

24. Couture AD, E. Lebrun S, Hoarau C, Grandclaude P. An expeditious synthesis of goniotalactam. *Nat. Prod. Lett.* 1999; 13:33–40.
25. Ding D, Meng Q, Gao G, Zhao Y, Wang Q, Nare B, Jacobs R, Rock F, Alley MR, Plattner JJ, Chen G, Li D, Zhou H. Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents. *J Med Chem.* 2011; 54:1276–1287. [PubMed: 21322634]
26. Ashford SW, Grega KC. Oxidative cleavage of 1,3-dicarbonyls to carboxylic acids with oxone. *J Org Chem.* 2001; 66:1523–1534. [PubMed: 11312995]
27. Guo W, Li J, Fan N, Wu W, Zhou P, Xia C. A simple and effective method for chemoselective esterification of phenolic acids. *Synth. Commun.* 2005; 35:145–152.
28. Huang S, Petersen TB, Lipshutz BH. Total Synthesis of (+)-Korupensamine B via an Atropselective Intermolecular Biaryl Coupling. *JACS.* 2010; 132:14021–14023.
29. Del Zotto A, Amoroso F, Baratta W, Rigo P. Very Fast Suzuki-Miyaura Reaction Catalyzed by Pd(OAc)₂ under Aerobic Conditions at Room Temperature in EGME/H₂O. *Eur J Org Chem.* 2009; 1:110–116.
30. Duggan ME, Imagire JS. Copper(I) Chloride Catalyzed Addition of Alcohols to Alkyl Isocyanates. A Mild and Expedient Method for Alkyl Carbamate Formation. *Synthesis.* 1989; 2:131–132.
31. Subramanian LR, Hanack M, Chang LWK, Imhoff MA, Schleyer P. v. R. Effenberger F, Kurtz W, Stang PJ, Dueber TE. On attempts at solvolytic generation of aryl cations. *J. Org. Chem.* 1976; 41:4099–4103.
32. Lodola A, Mor M, Rivara S, Christov C, Tarzia G, Piomelli D, Mulholland AJ. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. *Chem Commun (Camb).* 2008; 2:214–216. [PubMed: 18092091]
33. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. *J Biol Chem.* 2003; 278:22644–22649. [PubMed: 12682043]
34. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. *Drug Metab Dispos.* 2008; 36:995–1002. [PubMed: 18322075]
35. Henton DRA, K. Manning MJ, Swenton JS. Chemistry of quinone derivatives. Quinone monoketals via hydrolysis of electrochemically derived quinone bisketals. *J. Org. Chem.* 1980; 45:3422–3433.




Figure 1.
Design of peripherally restricted FAAH inhibitors.







Figure 2. Inhibition of brain FAAH activity by analogues of **3** bearing different substituents on the meta- position of the distal phenyl ring; a) Dose-dependent effects of secondary (**7c**), tertiary (**7d**) or reverse (**7e**) amide derivatives of compound **3** in Swiss Webster mice; doses were 0.3–40 mg/kg (subcutaneous); FAAH activity was measured *ex vivo* 1 h after injection; b) Dose-dependent effects of sulfonamide (**7f**) and methylsulfone (**7g**) derivatives of compound **3** in Swiss Webster mice; doses were 0.3–75 mg/kg (s.c.); c) Effects of pharmacological blockade of the Abcg2 transporter (Ko-143, 15 mg/kg, i.p., closed bars) on brain inhibition of FAAH activity by a sub-effective dose (selected from the dose-response study: **3** (25); **7d** (10); **7e** (1); **7f** (40); **7g** (1) in mg/kg, s.c., open bars) of analogues of compound **3** bearing different functionalities on the meta- position of the distal phenyl ring. Results are expressed as mean \pm s.e.m. (n = 3-4). *** $P < 0.001$ vs non-Ko-143 treated group.

**Figure 3.**


Inhibition of brain FAAH activity by analogues of compound **3** bearing different substituents on the meta- or para- position of the proximal phenyl ring; a) Dose-dependent inhibition of brain FAAH activity by *p*-hydroxymethyl (**21**), *p*-carboxyl (**29**), *p*-sulfate (**30**) and *m*-hydroxy (**35**) derivatives of compound **3** in Swiss Webster mice; doses were 0.3–75 mg/kg (s.c.); b) Effects of pharmacological blockade of the Abcg2 transporter (Ko-143, 15 mg/kg, i.p., closed bars) on brain inhibition of FAAH activity caused by a sub-effective dose (selected from the dose-response study: **3** (25); **21** (10); **29** (40); **30** (75); **35** (40) in mg/kg, s.c., open bars) of analogues of compound **3** bearing different functionalities on the meta-position of the distal phenyl ring. Results are expressed as mean \pm s.e.m. (n = 3-4). *** $P < 0.001$, ** $P < 0.01$ vs non-Ko-143 treated group.

**Scheme 1.**


Reagents and conditions: a') BBr₃, DCM, -78 °C, 2 h, 97%; b') ArB(OH)₂, CsOAc, PdCl₂dppf, dioxane, 80 °C, 5–12 h, 16–62%; a'') ArB(OR)₂ (**5d,e**) or ArB(OH)₂ (**5f,g**), CsOAc, PdCl₂dppf, dioxane, 80 °C, 3–12 h, 19–77%; b'') cyclohexene, 10% Pd/C, EtOH, 60 °C, 2 h (**7d,f,g**) or BBr₃, DCM, -78 °C to rt, 2 h (**7e**), 56–90%.

**Scheme 2.**


Reagents and conditions: a) ArB(OH)₂, Na₂CO₃, Pd(PPh₃)₄, toluene/H₂O, reflux, 12 h, 64–78%; b) *c*-C₆H₁₁NCO, Et₃N, CH₃CN, reflux, 5 h, 55–61%; c) H₂ (4 atm), 10% Pd/C, EtOH/EtOAc (**11b**) or EtOH (**11a,c**), 50 °C, 4 h, 19–50%.

**Scheme 3.**


Reagents and conditions: a) i) *m*-CPBA, DCM, 40 °C, 72 h; ii) NaOCH₃, EtOH, rt, 1 h, 60%; b) 3-carbamoylphenylboronic acid, Na₂CO₃, Pd(PPh₃)₄, toluene/H₂O, reflux, 12 h, 81%; d) *c*-C₆H₁₁NCO, Et₃N, CH₃CN, reflux, 2 h, 77%.

**Scheme 4.**


Reagents and conditions: a) ethylene glycol, *p*-TSA, toluene, reflux, 12h, 93%; b) *t*-BuOK, BnOH, dry dioxane, 85 °C, 1 h; c) 2 N HCl, rt, 2 h, 75% (over 2 steps); d) ArB(OH)_2 , K_2CO_3 , Pd(OAc)_2 , EGME/ H_2O (3:1), rt, 40 min, 95%; e) NaBH_4 , EtOH, 0 °C to rt, 2 h, 81%; f) 10% Pd/C, γ -terpinene, dioxane, reflux, 1 h; g) *c*- $\text{C}_6\text{H}_{11}\text{NCO}$, Et_3N , $\text{CH}_3\text{CN/EtOH}$, rt, 12h, 44% (over 2 steps).

**Scheme 5.**

Reagents and conditions: a) AcCl, ZrCl₄, DCM, 0 °C to rt, 1 h, 55%; b) diethyl oxalate, *t*-BuONa, THF, rt, 30 min, 77%; c) Oxone®, acetone, 0 °C, 2 h, 61%; d) BBr₃, DCM, 0 °C to rt, 12h, 61%; e) BnBr, KHCO₃, DMF, rt, 12h; f) 3-carbamoylphenylboronic acid, PdCl₂dppf, K₂CO₃, dioxane/H₂O, 90 °C, 1 h, 57%; g) *c*-C₆H₁₁NCO, Et₃N, CH₃CN/EtOH, 45 °C, 12h, 76%; h) 10% Pd/C, cyclohexene, dioxane, 80 °C, 2 h, 44%.


**Scheme 6.**

Reagents and conditions: a) *t*-BuONa, BnOH, dry DMF, 90 °C, 3 h, 72%; b) 3-carbamoylphenylboronic acid, K₂CO₃, Pd(OAc)₂, EGME/H₂O (3:1), 60 °C, 20 min, 70%; c) 10% Pd/C, cyclohexene, dioxane, 80 °C, 2 h, 100%; d) *c*-C₆H₁₁NCO, CuCl, DMF, rt, 30 min, 29%.

**Scheme 7.**

Reagents and conditions: a) $(\text{CF}_3\text{SO}_2)_2\text{O}$, DMAP, DCM, 0 °C to rt, 15 min; b) 3-carbamoylphenylboronic acid, Na_2CO_3 , PdCl_2 , EtOH, reflux, 12 h, 45%; c) BBr_3 , DCM, 0 °C to rt, 30 min, 40%; d) $c\text{-C}_6\text{H}_{11}\text{NCO}$, Et_3N , CH_3CN , reflux, 2 h, 65%.

Table 1


Inhibitory Potency (IC₅₀) and Systemic Distribution of 3'-Substituted *O*-Biphenyl-3-yl Carbamates.


	R	In vitro IC ₅₀ (nM) ^a	FAAH inhibition in liver (%) ^b	FAAH inhibition in brain (%) ^b	PSA (Å ²) ^d
3	CONH ₂	2.0	91.7±0.7	-3.0±8.0	83
7a	COCH ₃	0.3	88.1±0.8	89.2±0.6	62
7b	COOH	32	30.0±2.6	2.8±1.3	77
			66.4±4.1 ^c	-6.8±2.7 ^c	
7c	NHCOCH ₃	15	76.0±1.6	31.6±1.5	72
7d	CONHCH ₃	6.0	87.2±2.4	0.9±3.7	73
7e	CON(CH ₃) ₂	1.5	84.2±2.5	22.6±7.8	65
7f	SO ₂ NH ₂	2.7	81.1±1.3	7.0±1.7	99
7g	SO ₂ CH ₃	6.3	73.9±4.6	6.6±2.3	78
11a	CH ₃	2.5	72.1±4.9	85.4±0.5	49
11b	CH(OH)CH ₃	2.0	80.9±0.9	89.6±0.6	65
11c	CH ₂ OH	1.6	86.6±0.6	88.6±0.7	66

^aIC₅₀ measured in membrane preparations of Wistar rat brain^bFAAH inhibition measured ex vivo 1 h after injection in Swiss Webster mice (1 mg/kg, intraperitoneal, n = 3)^cFAAH inhibition measured ex vivo 1 h after injection in Swiss Webster mice (3 mg/kg, intraperitoneal, n = 3)^dPSA values were calculated using ICM version 3.7 (Molsoft LLC, San Diego, CA).

Table 2

Inhibitory Potency (IC₅₀) and Systemic Distribution of 5-(or 6-)Substituted 3'-carbamoyl-*O*-biphenyl-3-yl Carbamates.



	R ¹	R ²	In vitro IC ₅₀ (nM) ^a	FAAH inhibition in liver (%) ^b	FAAH inhibition in brain (%) ^b	PSA (Å ²) ^d
3	OH	H	2.0	91.7±0.7	-3.0±8.0	83
15	OCH ₃	H	0.5	94.6±0.7	86.4±2.1	74
21	CH ₂ OH	H	1.2	91.5±1.1	10.5±1.5	83
29	COOH	H	2100	86.3±1.3	-2.1±0.5	94
30 ^c	OSO ₃ NH ₄	H	34	84.0±1.2	-11.7±2.6	117
35	H	OH	0.5	89.5±1.1	-4.2±2.5	84
41	H	OCH ₃	2.0	85.6±2.4	82.6±0.4	74

^aIC₅₀ measured in membrane preparations of Wistar rat brain

^bFAAH inhibition measured ex vivo 1 h after injection in Swiss Webster mice (1 mg/kg, intraperitoneal, n = 3)

^c**30** was obtained from **3** upon treatment with SO₃-DMF complex in dry DCM (see experimental section for further details)

^dPSA values were calculated using ICM version 3.7 (Molsoft LLC, San Diego, CA).